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Introduction: The Canada Health Act (CHA) requires provincial/territorial governments to 
publicly fund prescription drugs when delivered in the hospital. This coverage does not continue 
once individuals are discharged under the terms of the CHA. Governments do provide additional 
public coverage for drugs outside of the hospital for specific groups. The Ontario Drug Benefit 
Program (ODB) was implemented in 1974 to provide public funding for prescription drugs for 
seniors 65 years and older.  
 Methodology: The data collection for this case study is based on a scoping review (peer review 
and grey literature) and semi-structured interviews. Relevant documents were identified from the 
Ontario government’s websites, professional associations, and searches with Medline, PubMed, 
Econlit and Ovid. Ten physicians working in a Durham region primary care clinic in Ontario 
were interviewed to determine their views on the ODB program. An iterative approach was used 
to analyze the data and resulted in the identification of several different themes related to both 
the benefits and challenges of the ODB for physicians and their patients. 
Results: Physician views were concentrated on transparency regarding the ODB’s decision 
making process for inclusion/exclusion on the ODB formulary, the need for timely information 
when brand name drugs are replaced with generic drugs (i.e., communication about and 
information on the generic), and on the challenges of completing ODB forms to request coverage 
for non-formulary drugs. Concerns were raised about the potential negative side effects of the 
replacement drugs for their patients. While it was recognized that generic drugs are less costly, 
this saving needs to be balanced with the costs associated with the impact the replacement drug 
may have on patient outcomes. Procedures to request public funding for prescription drugs not 
covered under the ODB program need to be streamlined to ensure patients have timely access to 
the appropriate drug within the publicly funded program (i.e. the Exceptional Access Program). 
The primary care physicians did also express that they were pleased with the fact that Ontario 
had such a program to offer to the senior population as they are the population suffering with the 
most co-morbidities. 
Discussion/Conclusion: The implementation of a national pharmacare program in Canada has 
the potential to reduce costs and increase access. Results from this study suggest that certain 
challenges exist in obtaining the most appropriate drugs for individual patients. Challenges exist 
that impact the quality of care and costs associated with procedural requirements. Other lessons 
learned from this study suggest the importance of including physicians when making policy 
based decisions in healthcare because they are the gatekeepers of medicine.  
Key Words: Ontario Drug Benefit (ODB), Ministry of Health and Long-term Care (MOHLTC), 





Why me and the Ontario Drug Benefit (ODB) Program? 
 As a student, I always knew I would like to pursue a career heavily involved in 
healthcare. As such, I was given an amazing opportunity as a young teenager to work for six 
general practitioners in a very busy clinic. I have been a part of this healthcare environment for 
the past eight years and have grown to love the healthcare environment as time progressed. The 
experience I gained at a very young age, allowed me to learn aspects of the healthcare system 
that only would be learned with age, and with a career in the healthcare system. I am truly 
grateful for this amazing opportunity, and as such, it has shaped me into the driven person I am 
and has fed my passion for the healthcare interface. Throughout the eight years that I have 
worked in the clinic, I have been given opportunities to work in several different offices, as well 
as the urgent care clinics in town.  
 
My exposure at an early age to the healthcare interface allowed me to learn about certain 
aspects of healthcare delivery and health policy, and to observe from firsthand experience, some 
of the weaknesses, strengths, pros, and cons of different aspects of the current healthcare system 
in Ontario. As such, I decided to pursue a graduate degree in healthcare with the hopes of 
pursuing a future career in health promotion. As I began a Master’s degree at the University of 
Ontario Institute of Technology (UOIT), I took the opportunity to focus on one aspect of health 
policy. I decided to formulate my research question surrounding the Ontario Drug Benefit 
program (ODB) because it is an area in need of more research. This area included working with 
the ODB program, more specifically, examining Section 8 Forms, The Exceptional Access 










Glossary of Terms 
 
C 
CED: Committee to Evaluate Drugs (formerly known as the Drug Quality and Therapeutics 
Committee)  
D 
 DQTC: Drug Quality and Therapeutics Committee (was established in 1968, now is referred to 
as the Committee to Evaluate Drugs) 
E 
EAP: Exceptional Access Program  
L 
LU codes: Limited Use codes 
M 
MOHLTC: Ministry of Health and Long-term Care 
N 
NICE: National Institute for Clinical Excellence 
T 
TPD: Therapeutic Products Directorate of Health 
 










1.1 Statement of the Problem 
 
The Canada Health Act (CHA) requires provincial/territorial governments to cover 
prescription drugs when delivered in the hospital (CHA, 1984). This coverage does not continue 
once individuals are discharged. However, governments do provide additional public financing 
for some groups of people. The Ontario Drug Benefit program (ODB) was implemented in 1974 
to provide public funding for drugs for seniors 65 and older and needing financial assistance 
(Ministry of Health and Long-term Care [MOHLTC], 2011). Beginning August 1, 1975 all 
seniors 65 years and over were eligible for coverage under the ODB program (MOHLTC, 2011). 
Not all drugs, however, are covered by the ODB program. It is especially challenging for seniors 
on fixed incomes suffering from multiple chronic conditions to privately fund drugs not covered 
by the ODB program. Non-adherence to necessary drug therapies can potentially negatively 
impact seniors’ health conditions and outcomes. Seniors who are unable to adhere to their 
medication regimens due to the inability to pay are at a greater risk because they are the 
population suffering from the most co-morbidities (Irvine, Ferguson & Cackett, 2005). 
According to Laupacis (2002) the policies and procedures that govern the ODB program 
can make it difficult for prescribing primary care physicians. Godwin, Chapman, Mowat, Racz, 
Mcbride andTang (1996) indicates that there is a need for research on how primary care 
physicians can be included in future formulary decision making changes.  
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Limited information is available in the literature on the ODB program. Furthermore, there 
is no data in the literature on primary care physicians’ perspectives regarding the ODB program. 
The aim of this study was to explore some of the advantages and disadvantages present in the 
ODB formulary coverage program and how it can be limiting for prescribing primary care 
physicians. The aforementioned will be examined from primary care physicians’ perspectives 
based on a series of semi-structured interviews.  
1.2 Research Questions 
 
The purpose of this study was to:  
a) Explore and analyze the advantages and disadvantages of the ODB program, and 
b) Explore how the ODB impacts primary care physician prescribing behaviour for 
Ontarians aged 65 and older who qualify for coverage under the ODB program.  
The following were the research questions for this study: 
1. What is the Ontario Drug Benefit program? 
2. What is the purpose of the Ontario Drug Benefit Program? 
3. Who is eligible to receive services under the Ontario Drug Benefit Program and why? 
4. How can the Ontario Drug Benefit program be improved from the primary care 
physicians’ perspective? 
5. What are the advantages and disadvantages of the Ontario Drug Benefit program 





1.3 Overview of the Steps Taken to Address the Research Questions 
 
The following overview summarizes how the rest of the chapters in the thesis project 
identify the research questions that are listed above. 
Chapter 2 provides an overview of what is available in the literature in terms of national 
health policy, provincial health policy, the ODB program, the history of the ODB program, 
generic drug costs in Canada, and the importance of health policy research. This information 
constitutes the scoping review, and its purpose is to answer the first three research questions. 
Chapter 2 also supports why studying the ODB program is important and illustrates the lack of 
research found in the literature related to this field. 
Chapter 3 outlines the methodological approaches used for this study. Chapter 4 contains 
the results and analysis from the key informant interviews. Chapter 5 is a discussion of the 
specific details and findings of the research project; the conclusion to Chapter 5 addresses the 











 2.1 Background 
 
The Canadian healthcare system is publicly funded, but privately delivered (Irvine, 
Ferguson & Cackett, 2005). It is based on five principles: health care must be universal, 
portable, comprehensive, accessible, and publicly administered as defined in the Canada Health 
Act (Canada Health Act, 1984).  
Universality requires that all Canadians must be insured for all public health services, 
meaning all insured services are available to the residents, everywhere. Portability demands that 
the provinces and territories in Canada must cover insured health services to all Canadians even 
when they are out-of-province or territory of residence or out of Canada. Comprehensiveness 
describes that all medically necessary procedures are insured and covered for Canadians.  
Accessibility defines that all Canadians have equal access to insured health services without 
discrimination against income, age, or health status. Lastly, publicly administered healthcare can 
be defined as each province or territory must insure all medically necessary services for which 
Canadian citizens are not required to pay according to the CHA (Canada Health Act, 1984; 
Madore, 2005). 
Despite the fact that these five principles are required to be met by each province or 
territory in Canada to receive federal funding for healthcare (Canada Health Act, 1984; Madore, 
2005), these principles have been frequently debated and implemented inconsistently (Charles, 
Lomas & Giacomini, 1997). The comprehensive principle says drugs are funded in hospital but 
this funding does not continue once the patient is discharged from the hospital. As noted above, 
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the principle of comprehensiveness ensures that all services deemed medically necessary are 
insured (Canada Health Act, 1984; Madore, 2005). Furthermore, the CHA does not specify 
exactly which services will be covered for Canadian residents, and therefore each 
province/territory defines which services will be covered and which will not. According to 
Madore (2005), many people believe that the concept of comprehensiveness is not necessarily 
being reflected when delivering healthcare services because the definition differs depending on 
which province/territory the healthcare services are being offered in. 
2.2: What is the Ontario Drug Benefit Program (ODB)? 
 
On September 1, 1974, the Ontario Conservative government implemented the ODB 
program for seniors 65 years of age or older. The ODB program provides public coverage for a 
variety of medications. The ODB formulary is a list of 3,800 medications that are publicly 
funded for Ontario residents 65 years of age or older, for those on social assistance, for those 
living in special care homes and long-term care facilities, and for those receiving professional 
services at home (Ministry of Health and Long-Term Care, 2011). In an effort to use cost-
effective measures, the Committee to Evaluate Drugs (CED), formerly called the Drug Quality 
and Therapeutics Committee (DQTC), makes a recommendation to the Executive Officer of the 
MOHLTC about which drugs should be included on the ODB formulary (Laupacis, 2002; Paus 
Jenssen, Singer, & Detsky, 2003; Ministry of Health and Long-Term Care, 2013). These 
recommendations are available to the public on the MOHLTC website. To assist in this process, 
in 1996, the Ontario government required that pharmaceutical companies who want their drug 
product listed on the ODB submit a formal economic analysis that outlines the drug’s cost-
effectiveness (Paus, Jenssen, Singer, & Detsky, 2003). The CED is made up of 16 members who 
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are appointed by Orders in Council (Ministry of Health and Long-Term Care, 2013). Two of the 
16 members are patients, and the rest of the 14 members are physicians, pharmacists, and an 
economist (Ministry of Health and Long-Term Care, 2013). For each drug that is brought to the 
committee’s attention from a pharmaceutical company, a recommendation is made to the 
Executive Officer of the MOHLTC who decides whether that particular drug makes it to the 
formulary or not. Once the Executive Officer has decided that the drug will be added to the 
formulary, there are three categories in which the drug can be categorized. These categories 
include General Benefit, Limited Use (LU) and The Exceptional Access Program (EAP)/Section 
8.  
2.2.1 General Benefit. 
 
General Benefit means the drug is covered for all patients who qualify under the ODB 
program with no restrictions. The drugs found in the ODB formulary are all considered as a 
General Benefit. 
2.2.2 Limited Use (LU). 
 
 Limited Use (LU) is defined as the drug will only be fully covered if the patient meets 
certain clinical medical conditions or criteria for the drug. If a drug is not on the formulary under 
a General Benefit, then the drug may be considered an LU product. In order to ensure that the 
patient who qualifies for LU coverage receives the funded drug, the physician will write the 
prescription for the LU medication by including the code or the number that signifies funding 
eligibility. For example, Ciprofloxacin is a common antibiotic used to treat skin/soft tissue joint 
infections, urinary tract infections, or some sexually transmitted diseases (Ministry of Health and 
Long-Term Care, 2013). The LU code that qualifies patients for funding for Ciprofloxacin for a 
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urinary tract infection for instance is 333. When the pharmacy receives the prescription with an 
LU code on it, the pharmacist submits the code to the MOHLTC and in most cases, funding is 
granted (MOHLTC, 2013). However, if the patient needs this medication for a reason that is not 
listed under the code, then the patient does not receive public coverage for it and therefore needs 
to pay for the drug.  
2.2.3 Exceptional Access Program (EAP)/Section 8 Request. 
 
The Exceptional Access Program (EAP) is a program that gives certain patients access to 
drugs that are not funded by the ODB program (Ministry of Health and Long-Term Care, 2011). 
If the drug is not listed as either a General Benefit, or an LU product, then the patient may 
qualify for coverage under the EAP. In some cases, the drugs listed in the formulary may not be 
clinically effective for some patients. Thus, the primary care physician prescribes medication that 
is not a General Benefit or an LU product, possibly resulting in economic burden for patients. 
However, a request (i.e., Section 8 form) may be made to the MOHLTC through the EAP to 
determine funding eligibility for particular patients for the unlisted drug (Ministry of Health and 
Long-Term Care, 2002). An example of the Section 8 form can be found in Appendix 1. Once 
the prescribing physician has completed the form with the necessary information, it is then 
reviewed by the CED and is either approved or denied by its Executive officer. The MOHLTC 
states that the majority of rejections occur because the physician did not give sufficient 
information on the form. Most requests take approximately three weeks to be processed and are 
sent back to the physician who made the section 8 request (MOHLTC, 2013). The EAP is not 
only related to the ODB program; those on social assistance through the Trillium Drug Program 
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(TDP) may also apply for coverage through the EAP. More information about the TDP appears 
below.  
 
2.2.4 Trillium Drug Program (TDP). 
 
The MOHLTC offers other programs including the Trillium Drug Program (TDP). The 
TDP provides drug coverage to patients in Ontario who have valid health cards, very high 
prescription costs, are below 65 years of age, are not eligible to receive social assistance, are not 
receiving Home Care services, and do not have private insurance coverage (Ministry of Health 
and Long-term Care, 2011; Godwin et al., 1996).  
The following chart (Figure 1) provides an overview of the process involved in 
identifying which drugs are included in the formulary and the process for identifying coverage 
for those drugs not considered a general benefit. Figure 1 (below) depicts the sequence of events 
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2.3 Changes to the ODB program 
 
 For those seniors on a very low income, they only pay a $2.00 deductible per 
prescription, however higher income seniors annually pay $100 plus $6.11 per prescription filled 
(Towers Watson, 2012). The new budget contained a proposal that high income single seniors 
(with an income greater than $100,000 per year) will be required to pay a $100 deductible plus 
3% of their income. For senior couples with a combined income of $160,000 or more, they will 
be required to pay a $200 deductible as well as 3% of their income. The co-payment per 
prescription will stay the same (Towers Watson, 2012). The purpose of the deductible is to help 
the government sustain the ODB program (Towers Watson, 2012). 
 
2.4 The History of the ODB Program 
 
The following section provides some background information on the development of the ODB 
program. 
The purpose of introducing publicly funded drug programs in Canada was to address the 
needs of those individuals who experienced financial barriers when accessing the drugs they 
medically need (Jacobs & Bachynsky, 2000). In 1974, drug coverage was introduced to the 
health care system in Ontario. Other provinces and territories followed but they created their own 
programs and policies for drug coverage as the health care system differs from province to 
province, since health is considered the responsibility of the province or territory (Deber, 
Gamble, Mah, 2010; Decter, 2005). Before the year 1970 however, there were very few drug 
coverage programs available for patients across Canada. The reason for this is that between 1955 
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and 1970, several new and expensive drugs were released into the market (Decter, 2005). These 
new drugs were mainly for the elderly population who were suffering from chronic illnesses (i.e. 
co-morbidities), as well as from a limited income (Decter, 2005). The Ontario government then 
initiated two programs that helped the elderly pay for their medications. These programs were 
generally referred to as Old Age Security (OAS) and Guaranteed Income Supplement (GIS). 
Although the OAS and the GIS were not directly linked to drug coverage, they still helped the 
elderly afford their medications (Jacobs & Bachynsky, 2000). Subsequently following the OAS 
and the GIS, drug benefit programs for the elderly, as well as those in need of social assistance 
were introduced to Ontarians such as the ODB program (Jacobs & Bachynsky, 2000).  
2.5 Potential challenges and concerns with the ODB Program 
 
The following section illustrates some common challenges and concerns in regards to the ODB 
program reported in the literature. This section illustrates the importance of studying the ODB 
program from physicians’ perspectives. 
Many physicians believe that the decisions made by the CED limit their ability to 
prescribe suitable medications for their patients. Suitable medications are especially important 
for those suffering from chronic diseases such as diabetes, hypertension, chronic pain, chronic 
obstructive pulmonary disease (COPD), and cardiovascular disease because they are required to 
be on numerous medications (Laupacis, 2002). As pointed out by Laupacis (2002), there are four 
reasons why a drug may not be considered as a General Benefit and therefore not included on the 
formulary; 
 Cost effectiveness when compared to treatments already on the market.  
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 The cost may be much higher than other already available treatment options. 
 The drug’s clinical effectiveness is not very well established in the available 
literature.  
 If the drug is only shown clinically effective for a certain group of patients and is 
not generalizable for most patients. 
Laupacis (2002) identified additional challenges with the ineffectiveness of the LU 
system as it poses problems to physicians who need to continually remember the specific codes, 
and pharmacists who need to contact the primary care physician’s office to retrieve the proper 
LU code on a prescription when the primary care physician forgets to include one. Often a 
patient is given a prescription with an LU code even though the patient may not qualify. The 
reason for this is to ensure the patient receives public coverage for a drug not listed under 
General Benefits but prescribed by the physician (Laupacis, 2002). This further reflects the 
challenges of the LU system since healthcare professionals are required to work around the 
policies and to provide their patients with the most appropriate medication. However, it is 
important to note that an LU drug is not as controlled as a drug that must go through the EAP 
and have a Section 8 form completed. In other words, it is not as complex of a process to provide 
a patient with coverage for an LU product compared to proceeding with the EAP with a section 8 
request.  
For example, the Multiple Sclerosis (MS) Society of Canada participated in the 
Government of Ontario’s drug strategy review in 2003, and as such they found that there were 
many areas in terms of drug coverage policies that needed improvement and that could in turn 
save the system money (Multiple Sclerosis Society of Canada, 2003). Their findings parallel 
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Laupacis’ points stated above, in that they provide a valid argument describing that four of the 
most effective MS treatments are not covered under the ODB formulary but are covered under 
the EAP and must have a Section 8 form in order to request coverage. The MS Society of 
Canada described their concerns that more recently, the Section 8 system has been used more as 
a cost saving tool as opposed to being something that can help offer Ontarians suffering with 
multiple sclerosis, better treatment (Multiple Sclerosis Society of Canada, 2003). This 
information provides further information supporting the need for more research regarding the 
rules and regulations governing the ODB program. There are concerns with the effectiveness of 
the Section 8 forms and drugs that are covered under the formulary. 
2.6 A Review of Drug Coverage Programs in Canada with Examples from Other Countries 
 
The following section outlines some information regarding other public drug coverage programs 
around the world in comparison to Ontario’s program. There are several other countries that, like 
Canada provide publicly funded healthcare to their citizens, and also have a similar public drug 
coverage program. Much can be learned from the procedures other countries have followed 
successfully. The following information can help to outline some of the pros and cons of the 
publicly funded drug coverage programs around the world.  
Drugs (both prescription and non-prescription) expenditure (including both public and 
private sources) is the second largest health expenditure category in Canada (Canadian Institute 
for Health Information, 2012). The sources for funding of drugs includes the public sector (i.e., 
provincial/territorial governments) and private sector which includes out of pocket payment by 
the individual and through private insurance such as employee benefits and/or individual private 
insurance (Canadian Institute for Health Information, 2012). Coverage for prescription drugs is 
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largely provided by the private sector at about 55% over the last 10 years (Canadian Institute for 
Health Information, 2012). A study comparing provincial drug coverage by Demers et al. (2008) 
demonstrated considerable variation in public coverage across Canada. In 2005, $24.8 billion 
was spent on drugs with $4 billion of this amount paid out of pocket by Canadian patients. 
Between 1998 and 2007, prescription drug spending increased from $8 billion to $19 billion 
(Canadian Institute for Health Information, 2011). In 2010, about half of the spending for 
prescription drugs came from the public sector (Canadian Institute for Health Information, 2011). 
Inequities exist; not all Canadians have similar levels of access to drug public coverage (Demers 
et al., 2008). 
A comparison of drug costs in Canada, the United Kingdom, Australia, and the United 
States demonstrated that drug expenditure is the fastest growing area in terms of total health 
expenditures for all countries (Clement, Harris, Li, Yong, Lee, & Manns, 2009; Gagnon, 2010). 
A cross country comparison by Clement et al. (2009) demonstrated that due to the increasing 
cost of drug measures have been put in place to control drug expenditures. This is achieved by 
creating groups of agencies that will determine which new pharmaceutical drugs will be covered 
in a publicly funded drug formulary, such as the CED in the case of the ODB program. 
However, resistance to the strategies put in place by governments exists. For instance, 
Godwin et al. (1996) made an observation that 60% of physicians in Scotland were against 
delisting some medications from their public drug formulary. This formulary is similar to the 
ODB formulary. The physicians were against these changes as they believed this affected the 
quality and delivery of care to their patients. They also found that the changes implemented 
limited their prescribing abilities and challenged their autonomy (Godwin et al., 1996).  
24 
 
2.7 Generic vs. Branded Drugs  
 
The majority of the drugs that are found on the ODB formulary are generic. According to 
a contact at the Ministry of Health and Long-term Care (MOHLTC), as of March 31, 2013, 60% 
of all the medications on the formulary will be generic. The following section outlines 
information on the generic drug market in Canada, but focuses specifically on the province of 
Ontario.  
Generic drugs are much more expensive in Canada when compared to the United States 
(Skinner & Rovere, 2008). The Canadian prices of the branded drugs are regulated by the 
Patented Medicine Prices Review Board (PMPRB) established by parliament in 1987 (CIHI, 
2012). Furthermore, Law, Ystma and Morgan (2011) conducted a study on generic drug pricing 
in Canada and noted that Canadians pay the most money for generic drugs compared to all other 
countries in the world (Skinner & Rovere, 2008). Generic drugs are known to help control the 
drug costs in Canada and they promote competition for brand name products once their patent 
protection has ended (Competition Bureau Canada, 2007). 
In 2006, Ontario attempted to make changes in the policies to reduce the costs expended 
by public drug plans such as the ODB program (Law, Ystma & Morgan, 2011). The 
determination of generic prices changed from 60-70% of the branded cost to approximately 50% 
in the ODB formulary at that time. Additionally in 2010, the government undertook initiatives to 
lower the drug cost expenditures so that the generic drugs covered in the ODB formulary would 
cost 25% of the branded cost instead of 50%. However, private insurers would continue to pay 
50% of the branded cost. By April 2012, generic drugs would cost 25% of the branded cost by 
law (Law, Ystma & Morgan, 2011). Improvements and changes were implemented in an effort 
25 
 
to reduce the cost of the generic drugs priced in Canada; although costs have been reduced, the 
generic drug pricing is still notably more expensive in Canada.  
The Competition Bureau in Canada has the responsibility to encourage and protect the 
competitive markets in Canada (Competition Bureau Canada, 2007). Despite the Canadian 
government’s efforts to eliminate the competition amongst branded and generic drug 
manufacturers, a competition still exists. Once a branded drug’s patent expires, a generic form of 
the drug can be manufactured. Before the drug patent expires, the branded drug manufacturers 
develop a strong relationship with the healthcare providers trying to build consumer loyalty to 
the drug even after it becomes generic (Skinner & Rovere, 2008). This can be referred to as 
direct consumer advertising where pharmaceutical companies encourage patients to ask their 
physicians to prescribe a specific medication (Skinner & Rovere, 2008; Ventola, 2011).  
The competition between generic and brand name drugs relies on demand, dispensing, 
distribution, and manufacturing (Competition Bureau Canada, 2007). The demand is determined 
by the prescribing primary care physicians in a given community based on the clinical 
effectiveness of the drug (Competition Bureau of Canada, 2007). In terms of dispensing the drug, 
most of the time the generic form is given to the patient, unless the primary care physician stated 
that the patient is unable to take the generic drug. Furthermore, some coverage plans may only 
cover generic drugs as this can be a cost-saver; patients may not have a choice regarding their 
preference for the generic or branded name. Manufacturing is based on the researchers who 
make generic drugs that are considered bio-equivalent to the branded name (Competition Bureau 
Canada, 2007). Approval must come from Health Canada for a generic drug to be released into 
the market (Competition Bureau Canada, 2007).   
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Davidoff (2001) argued the notion of “cost effective” drug treatments in health care. He 
reviewed a number of studies and challenged that a treatment that is considered “cost-effective” 
does not mean that money is being saved. In fact, he argued that it only provides medical 
treatment to the ill and it adds to the overall cost of care (Davidoff, 2001). He also concluded that 
the only treatments that are cost-effective are ones that are considered “cost-saving” meaning the 
treatment is proven most clinically effective and cheaper than other similar treatments (Davidoff, 
2001). Therefore, the question remains, is it really worth it for the MOHLTC to only provide 
coverage for generic drugs for patients when it is evident that the generic drug is not that much 
cheaper than the branded one? Evidently, many controversies exist in the health care system in 
regards to prescribing generic versus branded drugs, and generic drug costs versus branded drug 
costs. It is important to understand the differences in opinions within the healthcare system when 
it comes to comparing generic and branded drugs. There are strong arguments that state that 
choosing a generic drug does not mean that it is a cost saver. In this case, in an effort to use cost-
effective measures, the CED tends to choose the medication that costs the system less and still is 
shown to be clinically effective. That is why the majority of the drugs found on the ODB 
formulary are generic (MOHLTC, 2011).  
 
2.8 Current Issues. 
 
The following section outlines some important issues that are currently in the media regarding 
public drug coverage policies. This section strengthens the importance of this study as it adds to 




Recently, in June of 2012, Shoppers Drug Mart announced that they were launching a 
Health Care Portal website with the aim to improve healthcare delivery by providing primary 
care physicians with a tool to access drug reimbursement information. The portal also provides a 
number of different clinical tools, such as providing primary care physicians and nurses the 
ability to access drug reimbursement and clinical eligibility criteria for over 200 medications 
(Smitham, 2012). According to Smitham (2012) drug reimbursement policies can be very 
confusing for both the primary care physician and patient. Therefore, having a tool such as this 
one will help to improve delivery of care to patients to receive their necessary medications. The 
purpose of the tool is to provide clarity to assist in decision-making about which drug to 
prescribe.  
Universal Pharmacare in Canada has been addressed several times in discussions, 
conferences, and in the news (Picard, 2012; Gagnon, 2010). Picard (2012) stated that if Canada 
had a national public drug coverage policy, Canada would save more than $10.7 billion out of 
the $25 billion drug bill per year (Picard, 2010). Some comparisons were made with other 
countries adopting a publicly funded healthcare system such as the U.K., France, Australia, New 
Zealand and Sweden. All these countries have much lower drug prices compared to Canada 
(Picard, 2010). As indicated previously, generic drug prices in Canada are much higher 
compared to other countries (Lexchin, 2010). Furthermore, a recent article was released to the 
media in the summer of 2012 about Julie Easley’s struggle to survive. She was a recent graduate 
from the University of New Brunswick and was just diagnosed with Hodgkin’s lymphoma 
(Picard, 2012). Although her in hospital drugs were covered, her out of hospital care and her 
medications were not. While Ontarians have some access to drug coverage if they are on social 
assistance or suffering from chronic diseases and cannot afford their medications, (such as with 
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the Trillium Drug Program), New Brunswick did not have such a program. It was argued that 
Canada should have a national drug plan to help patients who are suffering from financial 
burdens due to the cost of their treatments. In response to this article, Steve Morgan, associate 
director of the centre for Health Services and Policy Research at the University of British 
Columbia in Vancouver, stated that there are many gaps in drug coverage policies within Canada 
which further supports the need for this type of research (Picard, 2012).  
In 2006, Ontario implemented the Transparent Drug System for Patients Act (TDSPA). 
The implementation of this Act caused a lot of controversies (Gagnon, 2010). The Executive 
Officer of the ODB program announced the implementation of the Act. The Act was 
implemented for several reasons, some of which include: 
 To improve patient access to drugs 
 To implement rapid drug reviews 
 To recognize pharmacists play a valuable role in patient care and patient counselling 
 To have funds set aside for conducting research to show drugs play an important role in 
healthcare treatment 
 To improve transparency and accountability in the drug system by allowing patients a 
role in the drug listing decisions and appoint an Executive Officer who will manage the 
publicly funded drug system 
 To reduce paperwork for primary care physicians by replacing the Section 8 process. 
(Ministry of Health and Long-Term Care, 2013).  
There is limited information about this Act in the literature. It seems as though there have 
been some improvements that have been implemented in the ODB program; however, it is 
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unclear whether these changes have been successful. The Act did, however, include a list of 
medications that are eligible for funding through the EAP through a phone service called the 
Telephone Request Service (TRS), as opposed to the traditional method of submitting a form. In 
this case, the physician would phone this service and request permission for coverage for a 
specified medication not covered as a general benefit on the formulary (Ministry of Health and 
Long-Term Care, 2013).  
2.9 Rationale for Study 
 
The following section provides a rationale for this thesis. Its aim is to summarize information 
from the scoping review above, and to support the need for this type of research. 
Laupacis (2002) states that further research is needed in the areas of LU codes and 
Section 8 policies in the ODB program. In accordance with Laupacis, Zwarenstein et al. (2007) 
indicates that there are gaps between what primary care physicians do in their clinical work and 
what the research evidence states should be happening in practice. Primary care physicians are 
affected by the policy decisions made by the MOHLTC in regards to the ODB formulary. Many 
primary care physicians feel that their opinions and perspectives should have been taken into 
consideration before the MOHLTC made changes to the ODB formulary (Godwin et al., 1996). 
In Godwin’s et al. (1996) study, they reviewed how delisting drugs from the ODB formulary 
affected the attitudes of prescribing primary care physicians in Kingston, Ontario. Throughout 
their review of the literature, they were able to find additional information from other countries 
in regards to primary care physicians’ opinions. However, they also stated that they were not 
able to find any reports on the effects of delisting drugs from the formulary in Canada. This 
further strengthens the need for this kind of research. Evidence is important to inform, develop, 
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and improve policies, practice, and public perception of a specific issue, such as with the ODB 
program (Suri & Clarke, 2009).  
Because the elderly in North America are considered the fastest growing population, they 
have the highest rates of co-morbidities (Grootendorst, O’Brien, & Anderson., 1997; Canadian 
Institute for Health Information, 2011). In 2015, it is predicted that there will be more seniors 
aged 65 and older than young youth (Canadian Institute for Health Information, 2011). With the 
growing senior population, several concerns have been raised about the Canadian healthcare 
system not being able to sustain the needs of the senior population. The senior population is 
known to frequently need healthcare services (Canadian Institute for Health Information, 2011). 
Due to this fact, researchers have gained more of an interest in healthcare policy for this age 
group, especially in prescription drug coverage, according to Grootendorst (et al., 1997). 
Furthermore, Allin and Laporte conducted a study in 2011 on the socioeconomic status of 
seniors and the use of medications in the ODB program. Their research aim was to find a gap in 
the drug policy in Ontario due to the potential inappropriate drug use in Ontario (Allin & 
Laporte, 2011). Their results showed that those individuals with a low income use more 
medications than those with a higher income. These facts further help to validate the rationale for 
this research project. Policy changes need to be made and the gaps in the ODB formulary 
policies need to be recognized amongst policy makers in Ontario.   
The Romanow report; Building on Values: The Future of Healthcare in Canada that was 
released in 2002 stated that prescription drugs are just as important medically compared to 
hospital and primary care physician visits, drugs for treatment, and other necessary health 
expenditures (Romanow, 2002). Kapur and Basu (2005) stated that there is evidence that the 
health and well-being of Canadians can be compromised if they do not have the proper access to 
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drug treatments for their health conditions. Furthermore, the Romanow report reveals several 
disparities in drug coverage across the nation (Romanow, 2002).  
Jacobs and Bachynsky (2000) have advised that a national initiative for a public 
pharmaceutical benefits program would further ensure proper prescribing, utilization, and cost 
effectiveness for the medications prescribed. This argument relates to the current discussion 
around the initiative of national pharmacare. If the governments in each province and territory 
agree to come together offering one national drug benefit program, it may be possible to realize 
improvements in the utilization of the program. Also, it would be much more feasible to study 
effectiveness by examining the nation as a whole (Jacobs & Bachynsky, 2000). Arguably, 
Rovere and Barua (2012) state that Ontario should follow in British Columbia`s footsteps and 
offer universal coverage for prescription drugs in the province based on need and not on age. 
A comprehensive review of the literature yielded limited literature in regards to the ODB 
program and primary care physicians’ perspectives on the ODB program. There were very few 
studies that examined drug coverage policies using the case study approach and interviews as a 
data set. 
Primary care physicians are the gatekeepers of the healthcare system (Health Council of 
Canada, 2010). They act as the main connection between patients and the healthcare system 
(Health Council of Canada, 2010). A report by the Health Council of Canada (2010) indicated 
that it is important to study the factors that influence primary care physician decision making. In 
doing so, the policies set in place can be improved in order to aid primary care physicians in 
making the best cost-effective choices to ensure best delivery of care (Health Council of Canada, 
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2010). This further supports the need for research in this area and provides a strong rationale for 
studying the ODB program from primary care physicians` perspectives. 
Although the ODB program provides services for several people in the population, this 
study focused on the senior population. To further support the need for this research, CIHI 
(2010) released a report outlining that between the years 2001 and 2006, the senior population in 
Canada grew to approximately 14% of the entire population. They also stated that because the 
senior population is growing this rapidly, there is a need for researching information in relation 
to seniors` drug use in order to improve management of public drug programs (Canadian 
Institute for Health Information, 2010). This research will help inform those in the healthcare 














The goal of this study was to determine primary care physicians’ perspectives on the 
Ontario Drug Benefit (ODB) program. This thesis explored the following research questions:  
1. What is the Ontario Drug Benefit program? 
2. What is the purpose of the Ontario Drug Benefit Program? 
3. Who is eligible to receive services under the Ontario Drug Benefit Program and 
why? 
4. How can the Ontario Drug Benefit program be improved from the primary care 
physicians’ perspective? 
5. What are the advantages and disadvantages of the Ontario Drug Benefit program 
from the primary care physicians’ perspective? 
 
The study is based on a case study approach (Yin, 2003). Data for this study was 
collected using semi-structured interviews. The analysis for this study is based on the theoretical 
framework that recognizes the interplay between ideas, interests and institutions which is 
explained further later in this chapter (Tuohy, 2003; Doern & Phidd, 1992; Béland, 2003). The 
scoping review conducted in Chapter 2 answered the first three research questions stated above. 
Primary care physicians’ perspectives were examined through semi structured key informant 
interviews. The key informants were asked about their views about the ODB program, their 
personal experiences with it, as well as their opinions on the advantages and disadvantages, and 
ways of improving the program. My role in this research project included being the principal 
investigator, conceptualization of the project, development of the research questions and the 
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research design, recruitment of key informants, conducting the key informant interviews, data 
collection, transcription of the data, and data analysis. The following sections describe in detail 
the methodology followed while conducting this research project. 
3.1 Study Design 
     3.1.1 Case Study. 
       
This research project is qualitative in nature. The research design used in this study is the 
case study approach. This method is most appropriate for this type of study since case studies are 
useful in the earlier stages of research project since this research project is meant to be a first step 
in developing a bigger project (2009). This method is used in order to achieve an understanding 
of the phenomena of which little is known as noted in Chapter 2. The purpose of this study is not 
to track physician prescribing behaviour through time, (e.g., prospective cohort study) but to 
better understand the current views of physicians on the ODB program. A case study design is 
advantageous because it allows the researcher to study contemporary phenomenon in its real-life 
context (Yin, 2011). Cases can be classified as individuals, groups, neighbourhoods, programs, 
organizations, cultures, or regions (Patton, 2002). The case study approach is most appropriate 
for this study due to the type of questions being asked. The case study approach allows the 
researcher to be able to address the “how” and “why” questions to the research problem. For 
example, answering why the ODB program was introduced and how the ODB program can be 
improved. Unlike an experimental design, this approach also does not involve any control over 
behavioural events and thus allows the researcher to study a phenomenon within its real life 
context (Yin, 2003). A survey design can focus on contemporary events like a case study; 
however this approach is better suited for answering questions about “how much” and “who.” 
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The purpose of this study is not to determine how many prescriptions physicians write but their 
experience with the ODB program. 
The case study approach works best when the consumers or users of a service are the unit 
of analysis, and in this case, the primary care physicians are the primary users of the service of 
the ODB program and they control patient access to the service (Yin, 2003). However, patients 
are also recipients and users of the service. 
As noted by Keen and Packwood (1995) the case study approach is very useful when 
investigating important policy questions in health care. They also stated that primary care 
physicians are interested in knowing how new government policies may affect the health of their 
patients. The ODB program was developed and implemented by the Ontario MOHLTC to ensure 
that the senior population has access to publicly funded medications. This study seeks to 
understand both the advantages and disadvantages of the ODB program. Results may potentially 
positively impact patient care by identifying gaps within the policy and suggesting changes that 
can improve delivery of the service. Primary care physicians will be asked to elaborate on 
personal encounters with their patients when they found themselves restricted in delivering what 
they thought was the best approach to treating their patients (Keen & Packwood, 1995). 
This case study focuses on a group of primary care physicians in a primary care clinic in 
a small town in Ontario. This is not the intent of the study. Rather the goals of this study: 
 Focuses on one primary care clinic in a small town in Ontario 
 Focuses on one group of primary care physicians in a small town in Ontario 
 Is not representative of all primary care clinics in Ontario or Canada  




3.2 Scoping Review. 
 
A research method commonly referred to as a scoping review was used when reviewing 
the literature for information on the ODB program. Scoping studies are used when the area being 
researched has not been extensively reviewed before (Arksey & O’Malley, 2005). Scoping 
reviews are slowly becoming more popular as a research methodology. In this study, the scoping 
method is most appropriate because the ODB program is a topic that is under-researched and not 
much is known about it (Arksey & O’Malley, 2005). In comparison to a systematic review, the 
scoping method is used when the topic being studied has not been studied much in the literature 
and allows the researcher to gather more general information about the topic being studied 
(Arksey & O’Malley, 2005; Goldner et al., 2011; Levac, Colquhoun & O’Brien, 2010).  
The scoping method has four main objectives: 
 To “map” what is currently available in the literature regarding the topic being studied. 
 To determine whether conducting a systematic review is appropriate for the topic being 
studied. 
 To provide a summary of the information available in the literature to the audience. 
 To identify gaps or areas that require more research about the topic being studied. 
(Goldner, et al., 2011) 
The scoping method for this study followed one similar to Goldner’s et al. (2011) approach: 
1. Developing the research questions 
2. Locating relevant publications/documents 
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3. Organizing publications used for study 
1. Developing the research questions:  
The first three research questions were used to guide the scoping review. The research 
questions were developed based on the difficulties experienced finding information about the 
ODB program. Since there was limited information available in the literature, I developed the 
first three questions which aimed to gather as much information as possible regarding the ODB 
program. The following were the questions used:  
1. What is the Ontario Drug Benefit Program? 
2. What is the purpose of the Ontario Drug Benefit Program? 
3. Who is eligible to receive services under the Ontario Drug Benefit Program 
and why? 
2. Locating relevant publications/documents: 
 Several literature searches were conducted to ensure that all information available in the 
literature that was related to the ODB program was identified. Several research databases were 
used from Brock University and UOIT’s library database. Searches using Google Scholar, 
Medline, PubMed, Econlit and Ovid (Medline) were conducted using the following search terms: 
 The Ontario Drug Benefit program 
 ODB 
 Limited Use codes 
 Section 8 requests 
 Generic drug costs 
 Branded drug costs 
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 Drug formulary 
 Health coverage 
 Physicians and the ODB program 
 Primary care physicians and the ODB program 
 Insurance plans 
 Pharmaceutical services 
 
There was very little information available in the literature in relation to the ODB program and 
as a result, an extensive search was completed. The criteria for the identification of articles to 
include for this study were based on the following;  
 Drug Formularies in Ontario, Canada and internationally, 
 Drug funding in Ontario and Canada, and 
 Views on drug formularies in Ontario, Canada and internationally. 
The following exclusion criteria was used: 
 Private insurance formularies, and 
 Cancer formularies. 
This criteria was selected because the purpose of this study was to better understand the ODB 
program which is a publicly funded program (i.e., not privately insured) for all Ontario seniors 




Once articles were identified using the keywords and multiple search engines, another search 
strategy was employed by reviewing the reference list of the identified articles. The review of the 
reference list also identified further articles to be included in the scoping review. The papers that 
were included in the scoping review needed to include information about the ODB program or 
drug coverage policies in Canada. All papers that were found were screened for relevance to the 
research questions (Arksey & O’Malley, 2005). 
3. Organizing publications used for study. 
 All the relevant information gathered specifically regarding the ODB program was 
organized based on the following themes; Background information regarding the CHA, What is 
the ODB program? Changes to the ODB program, The history of the ODB program, Potential 
challenges and concerns with the ODB program, A review of drug coverage programs in 
Canada and other countries, Generic vs. Branded medications, Current Issues, and Rationale for 
Study as illustrated in Chapter 2. As previously noted, the information gathered also informed the 
development of Figure 1 found in Chapter 2. This figure illustrates the drug categorizing process 
for the ODB formulary. 
3.3 Semi-Structured Interviews. 
 
Interviews allow researchers to study direct quotations from people involved in the study, 
about their experiences, opinions, feelings and knowledge in regards to the subject matter. This 
study used semi-structured interviews to collect the data from primary care physicians in a 
medical facility in Ontario  




 A letter was written and signed on behalf of a primary care clinic in a small town in 
Ontario to grant me permission to recruit physicians for the interviews. Thirty primary care 
physicians were initially invited to take part in the study and out of that number, ten agreed to be 
interviewed. The primary care physicians were e-mailed an invitation to participate in the study. 
This invitation can be found in Appendix 4. To increase the participation, after one month of 
sending out the invitations by e-mail, invitations were hand delivered to the primary care 
physicians present in the building, or they were placed in their mail-boxes. An interview time, 
date and location was set up as per their convenience for physicians who agreed to participate in 
the study.  
3.3.2 Data collection. 
 
The semi-structured interviews were conducted one on one with each primary care 
physician involved in the study. The length of the interviews varied, the majority were between 
20 to 30 minutes in length.  Prior to the start of the interviews, the primary care physicians were 
asked to sign the consent form (Appendix 3). If they did not feel comfortable being audio-
recorded, notes were taken instead. Out of ten primary care physicians interviewed, two did not 
wish to be audiotaped. Audio-recordings of the interviews were deleted and destroyed after they 
were transcribed.  
3.3.3 Interview Questions. 
 
The questions were developed with the help of the scoping review, and using other 
research interview guides as examples. Examples of interview questions from another qualitative 
case study were also used in developing the interview questions (Rifkin et al., 2010; Audulv, 
Asplund, & Norbergh, 2012; Martin et al., 2003).    
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 Since the number of people involved in the interview process is not very large, one on 
one interviews were a good choice (Gillham, 2000). Furthermore, other characteristics of the 
study that support one on one interviews as opposed to focus groups include:  
 The primary care physicians involved in the study are readily accessible. 
 Although the material being asked in the interview is not considered personal or 
sensitive, trusting the researcher is very important since personal opinions will be 
exposed. 
 The questions asked are open-ended and require a detailed response from the primary 
care physicians. 
 Responses from all primary care physicians involved in the study are crucial for the 
results and data of the study. 
 Lastly, the research aims to have a deeper understanding of the ODB program, as well as 
the views of the primary care physicians in regards to the program and its policies.  
(Gillham, 2000). 
Transcription of the recorded interviews was done by the principal investigator. All 
identifying information in the audiotapes was removed during transcription. Once the 
transcriptions were done, the principal investigator listened to the tapes a second time while 
following along with the transcribed notes to ensure accuracy. The interviews were conducted 
wherever was most convenient to the primary care physicians. The interviews were conducted in 
a private, quiet area to ensure a clear recording for transcription and to ensure privacy and 
confidentiality. The interview questions were tested for clarity and face validity. Clarity is 
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defined as whether the informants will understand the questions, and face validity is defined as 
whether the questions asked will answer what they are intended to answer (Yin, 2003). A 
primary care physician who was not part of the interview process and who did not contribute to 
the data collected, reviewed the questions. He provided feedback on their clarity and face 
validity prior to the commencement of the interview process.  
Primary care physicians were interviewed using the questions below to better understand the 
ODB formulary, drug coverage policies, Limited Use codes, and Section 8 forms/EAP.  
Interview Questions: 
1. In general, tell me about your experience with the Ontario Drug Benefit Program? 
2. Do you feel the Limited Use Codes and Section 8 Forms limit your prescribing abilities 
as a physician? 
3. Tell me what do you like most about the ODB program? 
4. How do you feel about the design of the ODB program? 
5. How could the program be improved? 
6. What are some changes you would like to see in terms of the rules, regulations and 
policies that surround the ODB program? 
7. Is there anything else you would like to say about the ODB program that was not covered 
in these questions? 
 
3.3.4 Sample Size, and Data Saturation. 
 
 In terms of sample size, according to Patton (2002), there are no set rules that one should 
follow for sample size when conducting qualitative research. However, choosing the ideal 
sample size does depend on what is being researched, the purpose of the interview, the resources 
available or not available to the researcher, as well as the time available (Patton, 2002). Sample 
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size also depends on whether the researcher is looking for breadth or depth in regards to the 
research question. The greater the sample size, the broader the results become. However, the 
smaller the sample size, the more in depth the data and analysis becomes. The purpose of this 
study is to collect in depth data on primary care physicians’ views on the ODB program because 
little is known about the ODB program.  
 The nature of the topic of this research is fairly well known amongst the primary care 
physicians and thus according to Morse, if the nature of the topic is clear and obvious, fewer 
participants are needed (2000). Morse (2000) also suggests that the exact sample size cannot be 
determined prior to collecting the data. She advises researchers to be flexible with the sample 
size in order for it to be determined once data collection has begun. Ten primary care physicians 
responded during the three month timeframe set aside for data collection. The first ten primary 
care physicians who responded during this timeframe were included in the study.   
3.3.5 Advantages and Disadvantages: Interviews. 
 
Although there are other techniques to collect data, data collected through interviews 
does have many advantages. One main advantage associated with face to face interviews 
includes the advantage of “social cues,” which may include voice, and body language that might 
indicate where the participants may feel uncomfortable with a question, or whether or not they 
are familiar with the topic under study (Opdenakker, 2006). Another benefit to face to face 
interviews includes no time delay between the question and the answer amongst the interviewer 
and the key informant. Additionally, having the face to face interview recorded provides a 
benefit to the interviewer where they have the chance to critically analyze the interviewed data in 
depth (Opdenakker, 2006). Lastly, an advantage to using face to face interviews would be the 
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ability the researcher has to reword, or explain a question that may not be understood by the key 
informant (Appleton, 1995).  
It is however important to note that there are disadvantages that accompany the interview 
process. Face to face interviews can be time consuming in terms of the length of the interview, as 
well as traveling time for the researcher and possibly the key informant. This was not the 
situation in this study as the interviewer traveled to the physicians and conducted the interviews 
where it was convenient for them. Due to the limited number of interviews this was not a 
problem. Accurate transcription is key for proper analysis and this depends greatly on the skills 
of the researcher (Appleton, 1995). This was dealt by listening to the audio-recordings a second 
time while reviewing the transcribed data to ensure reliability that the transcribed material is 
accurate. 
 
3.4 Research Ethics Board (REB) Approval. 
 This research proposal was sent to the Research Ethics Board at UOIT and received 
approval August 9, 2012. The REB file number is 12-023. The REB approval letter can be found 
in Appendix 2, as well as all other REB documents in Appendices 2 to 6. 
3.5 Data Analysis: Compiling, Disassembling and Reassembling. 
 
Data analysis proceeded in three steps. The data analysis part of this study followed a 
similar approach to that of Martin et al. (2003) study. A study was conducted in Canada at the 
University Health Network (UHN) by Martin et al in 2003 on the decision making process of 
which drugs make it to the hospital formulary. The researchers adopted a case study approach as 
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well and also conducted semi-structured key informant interviews. They used the case study 
approach because they felt it was the most appropriate methodological approach to use for the 
nature of their study and also, they stated that it is appropriate to use because priority settings in 
the hospitals is “complex, context-dependent and involves social processes” (Martin et al., 2003). 
Their study is quite similar to this one as they investigated the hospital drug formulary, they 
conducted semi-structured key informant interviews, and they also followed a case study 
approach to develop strategies that will help to improve the decision making process that the 
hospital follows when determining what drugs make it to the formulary and which do not. 
The data analysis for this study followed the steps illustrated below according to Yin (2011); 
Step 1: Compiling 
In the first step, the interviews were transcribed verbatim. Any identifying information 
was removed in order to ensure confidentiality of the participants. A coding sheet was kept and 
stored in a locked cabinet to further ensure confidentiality. The coding sheet revealed the 
participants’ names and their interview. Once all identifying information was removed from the 
transcribed data, the transcribed data was confirmed by listening to the interview tapes again. 
The transcribed data was then organized by interview question in order to make it easier for the 
next steps of the analysis process (Yin, 2011). 
Step 2 and 3: Disassembling and Reassembling 
 In the disassembling stage, the data was further broken down into smaller sub-categories 
to highlight specific themes found throughout the interview results. The reassembling stage 
involves reorganizing and rearranging the data in lists or in tabular form (Yin, 2011). The data 
was organized in tabular form (Please see Audit trail in Appendix 7, Table 2).  
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Step 4: Interpreting 
In step 4, the data was further broken down into the main themes that emerged from the 
transcribed data. In this stage, the reassembled data is used to create a more organized result of 
analysis of the data. Here, the main themes were laid out and specific quotes were chosen to 
illustrate these themes (Yin, 2011). Please see Table 2 in Appendix 7. 
Step 5: Concluding 
Here, the review of the literature was synthesized with the data collected to highlight and 
support the common themes found (Yin, 2011). The description was compared with the 
theoretical framework illustrated in Chapter 3, section 3.6; Historical Institutionalism. The 
results of the semi-structured interviews helped inform the researcher in writing the discussion 
section of the research. A primary care physician was part of the thesis supervisory committee. 
His contribution helped enhance the reflexivity of the analysis and was able to verify the findings 
to help address the validity of the findings (Martin et al., 2003). The committee member also 
contributed to the discussion and helped contextualize the data analysis once reviewing the 
results.  
3.6 Theoretical Framework: Historical Institutionalism. 
 
The theoretical framework is based on historical institutionalism which is defined as the 
interplay between ideas, structure and process (Doern & Phidd, 1992). This theoretical 
framework is used as a lens to guide data collection from the physicians. Theory helps to connect 
the researcher to the existing knowledge available in the literature and enables the researcher to 
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answer the questions why and how the phenomena are occurring as is the goal in this study 
(Brazil, Ozer, Cloutier, Levine & Stryer, 2005). 
Historical institutionalism is a theoretical approach to help understand the changes that 
have occurred in the healthcare system over time (Tuohy, 1999; Klein & Marmor, 2005; Béland, 
2010; Doern & Phidd, 1992). Furthermore, Putnam indicated that history plays a very important 
role in what occurs in the future (Putnam, 1993). According to this framework the decisions that 
were put in place in the past, whether intentional or accidental, have paved the road to the policy 
decisions that are made now and continue to be made by policy makers (i.e., decision-makers in 
government). In this study, as indicated earlier, the Canada Health Act (CHA) principle of 
comprehensiveness determines what healthcare services gets publicly funded. Drugs are 
universally publicly funded when delivered in a hospital. Drugs outside the hospital setting are 
not universally publicly funded. As a result provinces and territories have sought alternative 
strategies to provide public funding for specific groups outside of the hospital. Doern and Phidd 
(1992) describe policy as the result of the interactions amongst ideas, structure and process. Ideas 
are defined as the goals government hopes to achieve. In this study, government has a desire to 
provide public funding for seniors who need prescription drugs. Primary care physicians also 
share this goal in terms of their patient’s having access to medically necessary prescription 
drugs. Structure refers to the interest groups involved in the decision-making process and 
implementation of policy. For this policy area, interest groups include the primary care 
physicians, patients, government, pharmaceutical companies and pharmacies – all who have an 
interest in drug funding. Note that this study examines the views of physicians in regards to the 
ODB program. Process is defined as the instruments used to reach the desired goals. This study 
examines the regulation and funding strategies used to implement a drug formulary program. 
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The aim of this project is to view the ODB program from the primary care physicians’ 
perspectives. As such, the interplay framework guides data collection for this study as defined by 
Doern and Phidd. Physicians are one of few key stakeholders when discussing the ODB 
program. They are the frontline healthcare providers and therefore they can offer valuable 
information which supports data collection for this study. Similar frameworks have been 
developed by other researchers to understand policy development, decision making, 
implementation and goals (Doern & Phidd, 1992, Beland, 2005, Tuohy, 2003, Klein & Marmor, 



















Figure 2. Historical Institutionalism: The Interplay Framework-
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Interview Qualitative Results 
 
This chapter presents the results from the semi-structured interviews of 10 primary care 
physicians working in a primary care clinic in Ontario. Results are categorized based on the 
themes identified during the analysis. The main themes are illustrated in Table 1 below. The first 
section presents the overall views on the ODB program. The next section presents views on the 
overall sustainability of the ODB program. The third section presents the benefits and challenges 
of the ODB program. The fourth section presents views on Generic vs. Branded Drug use and 
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4.1 General opinions about the ODB program: Views vary 
The physicians were asked about their general experiences with the ODB program. Their 
views on the ODB program varied from physician to physician (see Table 2 in appendix 3). The 
general experiences described by physicians were either described as “excellent” or “not very 
good.” Each physician had their own personal opinion regarding the ODB program based on 
their own experiences with the ODB program. If their experiences were positive ones, they 
generally had very positive opinions about the program. However, if they had experienced 
difficulties with the policies surrounding the program or had not found it useful with their patient 
practice, they did not think highly of it. All physicians, however, did begin the interview by 
expressing their appreciation that a program such as this one exists. The physicians who have the 
majority of their practices made up of seniors, used the ODB program more than those who did 
not have as many elderly patients.  
Other physicians expressed their positive opinions about the existence of the ODB program: 
 
“…For the moment, as it is, it certainly goes a long way to help me and my ability to 
manage my patients’ illnesses.” 
 
“It’s an excellent program. It’s an essential program… So the program is essential and I 
think for the most part, is managed very, very well.” 
 
“I am happy ODB is covering medications for patients who have no other access to 
medications.” 
 
“Ok, well first of all I guess I’m glad that it’s there because it is an important safety net 





Although there were several positive aspects associated with the existence of the ODB program, 
some physicians had opposing views. Depending on their experiences, some of the primary care 
physicians were not as pleased with the program as others. The primary care physicians who had 
not been practicing for longer than five years or who had immigrated to Ontario from another 
country, found it difficult to work with the ODB program. There are several policies and rules 
that govern the program: 
“I don’t think it’s the best program out there.” 
“Very limiting for prescribing medication” 
 
 
4.2 Questioning the sustainability of the ODB Program:  costs associated with the program 
 
Some primary care physicians described their concerns with the costs associated with 
sustaining a program such as the ODB program. It can be quite challenging for primary care 
physicians to put their trust in the system when there is fear that it may not be realistically 
sustainable. Specifically when they agree the program is very beneficial to their patients: 
“The biggest challenge is the affordability of the strategy in the long term. You know as 
we have a population that is aging, a larger percentage of elderly, our use of this system 
will keep growing and what does that mean for the system as a whole? So I guess we will 
find out in time. For the moment, as it is, it certainly goes a long way to help me and my 
ability to manage my patients’ illnesses.” 
 The primary care physicians also recognized that some of the policies set in place 
governing the ODB program are essential in its sustainability. Although they are limiting and 
difficult to work with, the LU codes do seem to serve some purpose for some physicians. 
However, are the LU codes used properly? The lack of research in this area does pose several 
questions associated with the LU codes and other policies that are set in place with the ODB 
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program.  Physicians should be made aware of these potential issues as it makes their 
understanding of the program much better and allows them to use the program to provide the 
best care for their patients: 
“Is this something we can afford? I feel that the government is already using some ways 
like using the LU codes, so that physicians don’t abuse it in such a way that you don’t 
always use the most expensive drug, in lots of cases you can choose the less expensive 
drug and still do the job well, but because of marketing from drug companies, we have 
been bombarded by that and influenced by that somehow right?” 
 
“The problem is that, our whole healthcare system has a problem – we just don’t have 
enough money to fund everything.” 
 
“The biggest challenge is the affordability of the strategy in the long term. You know as 
we have a population that is aging, a larger percentage of elderly, our use of this system 
will keep growing and what does that mean for the system as a whole?...” 
 
4.3 Advantages and Disadvantages of the program 
4.3.1 Advantages. 
 
i. Increase access for those who are unable to pay. 
Although there are some disadvantages associated with the program, several primary care 
physicians did admit to the many advantages the program has to offer. One main advantage is 
definitely that the program caters to the senior population who suffer from the most co-
morbidities. There seems to be a gap in the system with patients who need certain medications 
but do not qualify for coverage (are not 65 or older) or who do qualify, but the medication is not 
available as a general benefit on the formulary 
 
“I don’t mind trying new medications for patients who have failed older medications, I’m 
just left giving them samples to see if it does work but it is a problem if it does work and 
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they don’t have the finances, or they are not in the program, or the program doesn’t 
accept coverage.” 
 
“I like the fact that it is available to people who are most disadvantaged.” 
 
“I’ve experienced better compliance after 65 compared to prior to 65.” 
 
“I guess it makes available to a large majority of our citizens who don’t have the means 
to afford medications, it makes medications easily available to them for the management 
of their health issues and chronic diseases so that’s probably the biggest single benefit as 
I’m sure you and I will benefit one day!” 
 
4.3.2 Flexibility in prescribing medication on the formulary. 
 
Other primary care physicians described some positive aspects with prescribing 
medications on the formulary. The fact that the formulary provides coverage for more than one 
drug in each drug class provides the physicians with flexibility in their treatment options for their 
patient: 
“The positive thing is they cover medications in the same groups (i.e. GI meds, 
cardiovascular meds etc…) giving me a chance to choose best one for patients. Gives us 
opportunity to choose in case patient reacts to one of the medications that they are 
prescribed.” 
 
“Now the business you run into is when you need to prescribe someone something that 
isn’t on the ODB list and then you have to decide yourself just how much of a fight you 
are going to put up with it because there are certainly products that are as equal as 
whatever you have chosen and certainly in lots of cases a whole lot cheaper. And that’s 
why the ODB – that’s their administration, they look after this drug, this drug, this drug 
and pick the one that’s going to be the cheapest if they are all going to be totally 
equivalent. I think I’m all in favour, I think it is an essential program and for the most 




“It is a good program – it cost government a lot. ODB is a good program but the section 8 
and de-listing of drugs and writing prescriptions differently to get coverage is what 
bothers me the most. If it is covered, it should be covered either way no matter how I 
write the prescription.” 
 
“But the fact that the program exists and I can always find something for my patients is 
what I like about it.” 
 
“In general, I’d been very happy with it, a large percentage of our patients who are on 
routine medications are often ODB candidate and by and large, most of the key 
medications that we prescribe are listed on the ODB so I have been happy with it.” 
 
“There is no medical problem that I have not found a medication for, it may not be the 
best, it may not be the newest or it may not be the one that has the most data out there but 
there is something for everybody on the program. That is what I like most about it.” 
 
 
Primary care physicians recognized the advantages of having a program such as the ODB 
program as it sets Canadians apart from the American healthcare system. The quality of care is 
important to primary care physicians.  
 
“I think if we didn’t have ODB, didn’t have drug coverage for these patients, it will be 
like the States, you have to choose between eating one day and your medication which is 
horrible so absolutely, there are good things about the ODB program.” 
 
 
4.3.3 Drug coverage by the ODB program 
 
When asked about the drugs that are available for coverage on the formulary, primary 
care physicians recognized the difficulties policy makers have when deciding which drugs are 
added to the formulary and which are not. Although there were several primary care physicians 
who did mention that it was beneficial for them to have more than one drug per class of drugs 
covered on the formulary, some described that this might be unnecessary. Reviewing the ODB 
formulary and how many drugs per class of drugs do qualify for a general benefit may provide 
more resources that can be allocated toward other more expensive drugs that are most commonly 
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used by physicians. The following quotes illustrate some physicians’ views on the inclusiveness 
of the drugs that make it to the formulary for coverage: 
“I think it’s good, I think its ok. I mean a lot of people might think they are restrictive, 
they are not very open to taking in more medications but I think whatever they are doing, 
they are doing well in a sense that there are quite a number of medications that I see there 
that I’m surprised that they are there, they are approved a lot. Not as much as the medical 
healthcare professionals would want, and I think the reason is this – the bias is – there is 
this new medication in town, and everybody feels is the wonder drug and the first 
question they ask is what about coverage? And I think it is because of the medical system 
we have in Canada, the universal healthcare, where everything in quote is free so you 
expect coverage.” 
“The way they take time and put medications on the ODB makes sense to me. Let’s say 
we have six medications that you can use for blood pressure. I don’t think all six should 
be put on the ODB. Maybe two, maybe three, they are doing the same thing, So I like the 




i. Adding new drugs to the ODB. 
Primary care physicians expressed what is unknown about the program. There is concern 
with what drugs make it to the formulary as a general benefit, and which do not, and why. There 
is a lag in the system with the new drugs that are introduced to the market and when those drugs 
are approved for coverage or not on the formulary: 
“Well I think for the most part, it is a pretty well run program. The only thing would be is 
the lag between what we think is a drug that should be covered and what they are going 
to cover…” 
“I would like to see more drugs covered under ODB like the new ones on the market…” 
 
“I wish the ODB would consider covering for more medications and provide less 




“I don’t think they should be de-listing drugs patients need unless they show studies that 
show they are not as effective as other meds etc… they should allow doctors to use 
discretion in prescribing meds.” 
These primary care physicians described their frustration with the different levels of 
benefit (I.e. General Benefit, LU codes and Section 8 requests/EAP). What is meant by different 
levels of benefit is the general benefit, LU codes, and the Section 8 requests/EAP. Primary care 
physicians asked for more consistency within the program. Making those drugs available for 
coverage provides physicians more flexibility in their prescribing abilities.  
“I think what’s frustrating is that the ODB has different levels of benefit, which requires 
different levels of process in order to get the benefit and that is frustrating, I’d like to see 
– if something is covered by ODB, then cover it, don’t give me different hoops to jump 
through to get it covered…” 
 
De-listing drugs from the formulary is also of concern. Primary care physicians are 
unaware when drugs are removed from the formulary until they try to prescribe it to a patient and 
are notified that it is no longer a general benefit. There are also some inconsistencies with how 
prescriptions are written. Some prescriptions are approved for coverage when written a certain 
way. These inconsistencies inhibit seamless delivery of care: 
“It is a good program – it cost government a lot. ODB is a good program but the section 8 
and de-listing of drugs and writing prescriptions differently to get coverage is what 
bothers me the most. If it is covered, it should be covered either way no matter how I 
write the prescription.” 
 









4.4 Generic vs. Branded Drugs 
 
4.4.1 Generic coverage 
 
The majority of physicians mentioned their concerns about the eligibility of medications that 
make it to the formulary, and how the majority of them are generic products. Some had strong 
opinions when comparing the generic and branded drug products on the market. For the most 
part, there seems to be consistency in that most primary care physicians feel confident that a 
generic form of a drug is just as effective as its branded form and therefore do not have any 
problems prescribing generic medications: 
 
“I have no problems with generic drugs because scientifically they should provide the same 
effects, I mean there are strict guidelines.” 
 
Some mentioned that they would like to see more testing and research done on the generic 
drug products. There seems to be more inconsistencies in generic vs. branded drug testing. 
Primary care physicians are concerned with the effectiveness of the generic forms of the 
medications on the formulary. Several questions arise such as how does the MOHLTC deal with 
some of the data in the literature that provides evidence that the generic form of certain 
medications are not as effective as their branded form? Policies need to be set in place to provide 
for more rigorous testing of generic drugs, and to provide stricter guidelines for generic 
manufacturers to meet: 
“There is some data that is out there that shows that generic drugs are not as effective as the 
name brand drugs and some of the policy changes that need to happen is a more rigorous 
testing of generic drugs…” 
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“...I would say not all medications are created equal. There are certain ones that I don’t have 
problems with but there are a few of them that have those kinds of issues.” 
“...I think if they were much stricter with the generic competitors with the tolerances in terms 
of the potency of medication so instead of plus or minus 15% make it plus or minus 5%. 
Make the generics much closer to what the brand names are in terms of potency, that would 
reduce the number of people who have complaints as they are making the transition.” 
 
Allowing more flexibility in prescribing behavior may help to address the issues with the 
generic medications: 
“I do have some patients – who do notice some differences for certain medications, but it is 
unusual for patients to say they want the original brand because it is not as effective…” 
 
One physician mentioned that there are times when a patient is automatically switched from 
the branded to the generic form of a medication once they turn 65 and are eligible for coverage 
under the ODB program.  When the patient is automatically switched from the branded to the 
generic form of the medication, there is not a policy set in place that requires the pharmacists to 
notify the physician. There were some instances where physicians recognized that if they had 
been notified that their patients were no longer on the branded form of a medication, they would 
have been able to avoid the occurrence of adverse reactions to the generic medication. A policy 
should be set in place where the pharmacists must notify the physicians when their patients are 
switched from the branded form of a drug to the generic. Notifying the primary care physicians 
will allow them to be more prepared when treating patients and to be aware that certain changes 
in their health may occur due to the change in the medication. It is crucial for the health and 
well-being of the senior population that physicians know when their patients are switched from 




“The pharmacy would probably come into play, like I would say, I don’t know if there could 
be a policy in place to say to the pharmacists once a patient starts on this medication, they 
need to stick with it and don’t change it, and if there is absolutely no way of doing it, then 
change it, but you need to notify the doctor…” 
  
 
4.5 Policy and regulation governing the ODB 
 
When it comes to the Limited Use (LU) codes and the Exceptional Access Program (EAP), 
several primary care physicians had very strong opinions towards these two aspects of the ODB 
program. Several mentioned the need to eliminate the EAP, and some mentioned that the LU 
codes could also be eliminated. On the other hand, there were also some primary care physicians 
who did not find a problem with the LU codes or the EAP. 
 
4.5.1 Limited Use Codes (LU). 
When asked about the LU codes, a couple of physicians mentioned that they are limited in 
their prescribing abilities if they need to follow the LU criteria. Some also mentioned that they 
still always somehow find a way to use the LU code and still provide their patients with the 
medication they need, even though the LU code they listed on the prescription is not completely 
correct. There seems to be ways around the policies set within the ODB program. Some primary 
care physicians become comfortable with the policies and find gaps within the program and are 
able to work around them and thus write prescriptions for their patients that they know will be 
completely covered: 




“The LU code which I don’t honestly see the point of, I’m sure other physicians feel the 
same way, really doesn’t inhibit me from prescribing medications because you are always 
able to find an indication which may not necessarily be the total honest way of doing it but if 
you feel the patient needs it you will circumvent that to get the medication.” 
 
“LU is ok, for most seniors. Once patient is able to get medication that they need, then I’m 
fine.” 
4.5.2 Removal of LU codes and EAP 
 
If the LU codes are not always followed correctly, then they are not serving their purpose. 
Several primary care physicians expressed their frustration with the LU codes and the Section 8 
requests. Primary care physicians believe that removing the LU codes and the Section 8 process 
will improve the ODB program and improve delivery of care to their patients. Primary care 
physicians should be given the autonomy to prescribe medication that they feel is appropriate for 
their patients: 
“Eliminate the red tape when it comes to other or newer medications which also have strong 
supportive evidence don’t go down the paths of LU codes or section 8.” 
“I would be happy to see the LU codes and section 8 forms – just get rid of them.’ 
“They need to remove section 8.” 
 
“I don’t see the point for us requesting special access for medications we think are best for 
our patients.” 
4.5.3 Timely Review of EAP Requests 
 
Many physicians described their frustration with the issue of the lengthy time it takes for 
the MOHLTC to return the EAP requests with a response. Little is known about the section 8 
process in the literature. 
“…I remember for a while, the EAP or section 8 process took a long time often times it takes 




“Most drugs we use with an LU and it goes through fine – but section 8 – they deny 
everything.” 
4.5.4 EAP Rejections 
 
Several physicians described their concerns with EAP rejections. Although there is limited 
information in the literature regarding the EAP program and section 8 requests, most physicians 
expressed that the majority of section 8 requests they have submitted to the MOHLTC have been 
rejected. The primary care physicians also mentioned that, sometimes, the section 8 requests that 
they have submitted take a very long time to be approved, leaving the patient with no treatment 
during that time period. Policies should be set in place to help primary care physicians deliver 
better care to their patients. However, if some primary care physicians are avoiding the section 8 
requests, then there certainly is a problem within the system: 
“… I have never had an experience where they have actually okayed it and said I could use 
it. My experience with section 8 is terrible.” 
“I hardly even do it now, if the medications are not easily covered on ODB, or LU, I 
probably avoid it…” 
 
Although there were concerns with EAP rejections, some physicians expressed no concern 
with the EAP, and noted that their requests were almost always approved in a timely manner. 
Inconsistencies toward this policy are apparent. Some physicians expressed extreme difficulty 
with receiving approval from the section 8 requests, and others mentioned that they do not have 
any concerns. Some primary care physicians submit the requests and receive an approval with no 
problems from the MOHLTC: 
“I don’t think after I have done it properly and dotted the I’s and crossed the T’s, I have 
ever had one refused. They are very, very good about that…” 
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“I don’t have experience with section 8 request being rejected – I am lucky so far” 
4.6 Transparency 
 
One very common theme that came up in every interview was the issue of transparency. 
Physicians wanted to know how the decisions are made in terms of implementing the policies 
surrounding the ODB program. Physicians wanted to also be included in the decision making 
process for the ODB formulary. Lastly, increasing education about the ODB program’s policies, 
rules, and regulations to physicians was also requested. 
4.6.1 Updating the ODB formulary. 
 
Physicians began by questioning how often the ODB formulary is updated and when it is 
updated. They want to be notified of the updates and changes when they are made. Somehow, 
the MOHLTC should provide primary care physicians with this information on a timely and 
regular basis: 
“They have a good number of medications really, I don’t know how often they update it, 
I’m not sure and it is difficult, I would say it’s me, because I guess I should find a way to 
actually know the medications that are there, but there are so many of them, how am I 
supposed to put them in my head?!” 
 
“I think for the most part, the ODB is fair, in terms of – it is evidenced based, they have 
tried to get the best evidence for which treatments work best for which diagnosis, there 
are some things that are clear – black and white, but there are a lot of things that are not 
clear and I think ODB has been very conservative in that and I think that is a good thing – 
being conservative in covering or not giving benefits to questionable treatments, so I do 
see ODB as being a very good program,…” 
“I would like to see more transparency in how they make decisions, right now it is really 




4.6.2 Importance of Evidence Based Practice to Physicians. 
 
Some physicians mentioned the importance of evidence based practice when making 
decisions in healthcare. The physicians are referring to how important it is for the MOHLTC to 
respond to the information resulting from evidence based medicine. They would like to see 
newer medications that are shown to be more clinically effective than the traditional ones found 
on the formulary. Sometimes it takes a long time before the MOHLTC recognizes the evidence 
and adds a new medication to the formulary or sometimes a medication that is shown to be 
clinically effective is not added at all. Doctors especially wanted to know whether the decisions 
are based on evidence based practice within ODB formulary: 
“It needs to be evidence based. Review the formulary more frequently than it is being 
reviewed from my experience, I mean I have only been here 6 years but I haven’t seen 
big changes in the formulary over the last six years, and medication that is already gone 
generic that shouldn’t be too costly, I can’t see on the program.” 
“Lack of evidence based, and lack of timely review. We do not get any notice of reviews, 
doctors are not aware of it. “ 
 
4.6.3 Reasons behind the policies and procedures. 
 
Another important subject that arose from the interviews is physicians wanting to be 
given detailed reasons as to why the government makes the decisions to include LU codes and 
the EAP program. Increasing the transparency in the decisions that are made that are associated 
with the ODB program is a recurring theme with the interviews: 
“I would like to know the reasons why we have to complete these codes and these forms. 
If they are just a pure financial reason, then they should be upfront about it.” 
 
“… I’d like to know who makes the decisions when we complete these forms, who 
actually determines the patients’ needs based on a piece of paper, and how objective that 
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can be and how they are able to determine the patients’ needs better than their own 
physicians.” 
“Be very transparent of the criteria for how medications get approved. So that the 
medical community - I mean they probably are and I don’t spend enough time to research 
it but just ensure that we have medications available to us that are widely recognized by 
evidence to be effective.” 
 The primary care physicians have not necessarily requested that all the policies be 
completely changed, but they have asked for increased education about the ODB program. If the 
MOHLTC creates a yearly conference or workshop for physicians, providing them with the 
chance to learn more about the program and about the policies set in place, then they will better 
understand the program: 
“We are cautious when it comes to cost and if they don’t think so, then they can educate 
us about cost effectiveness.” 
 
4.6.4 Informing physicians when drugs are delisted or added to the formulary. 
 
More physicians would like to be notified when drugs are delisted from the ODB 
formulary. The ODB formulary changes on a regular basis and sometimes drugs are delisted or 
added to the formulary and the primary physicians are not aware of these changes: 
 
“They take off drugs at various times on the list it’s hard to keep up with what they cover 
and what they don’t” 
 
Another physician admitted that the government does notify physicians of the changes 
made to the formulary: however, they would like a more productive way for the government to 
notify them. 
“…you know they do send updates all the time on what medications have been added to 
the formulary, what medications have been removed, it might be worthwhile to put a little 
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sheet that serves as a basic reminder of what basic policy is with the ODB, in other 
words, how do they select medications to stay, how do they select medications to be 
removed, why the policy, why the necessity of a LU code and a section 8 strategy.” 
 
4.7 Views on Recommendations and Suggestions 
 
Throughout the interviews, physicians made several recommendations and suggestions for 
improving the ODB program. One of the physicians expressed their belief in having one 
formulary for the entire country as opposed to it being broken down per province, also known as 
universal pharmacare.  
“My biggest – the thing that I really suggest and that’s the problem with the whole of 
Canada that’s what I have experienced because I lived in Manitoba and then moved to 
Ontario, it’s like we live in 8 different countries in one country. That’s the biggest 
problem. I think if they can have their buying power consolidated and have a single 
formulary for the whole country, that can be cost containment. The way they do it now is 
very expensive.” 
“I’m a novice at this but I expect every province has its own program running a different 
criteria, so medical care in Canada is not really universal as they would like it but you can 
imagine if you had one buyer for the whole 30 million people rather than 7 million here 
and one million there, you can argue much better pricing, you would have better 
medication on the formulary you wouldn’t be able to afford otherwise.” 
 
“You know, it always sounds nice in theory to make it more universal, in practice, I’m not 
really sure how feasible that is and how affordable that is.” 
 
One physician suggested designing a hybrid program for seniors as some seniors have 
more than enough money to fund their healthcare needs and some do not have a lot of money and 
cannot afford their medications.  
“…maybe some hybrid would be appropriate in the long run because we also have a 
population of 65 and 70 year olds who probably could afford to pay more than they do 
for their meds and as we are trying to create a cost containment strategy while 
maintaining the population health, I could a scenario arising where there is a means test 
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and what kind of subsidy you get for the medication depends on what your ability is to 


























Discussion and Conclusions 
 
The purpose of this study was to understand the ODB program from primary care 
physicians’ perspectives. This research can inform the MOHLTC so that they may benefit from 
the results of this study. This approach can be expanded upon to view the ODB program from 
other primary care providers, medical specialists, policy makers, pharmacists, patients, and other 
healthcare workers. Gaps in the literature as well as in the results will provide the evidence base 
for recommendations and suggested areas for improvement. This chapter section outlines a 
discussion regarding the themes that emerged from the results of the interviews.  
5.1 Theoretical Framework: Historical Institutionalism: Interplay Framework - Ideas, 
Structure, and Process. 
 
 Historical institutionalism was used as the theoretical framework in contextualizing the 
results of this study and to support data collection from the physicians since they are the frontline 
healthcare providers. The framework allows the researcher to understand the changes that have 
occurred over time in the healthcare system (Tuohy, 1999, Klein & Marmor, 2005; Béland, 
2010; Doern & Phidd, 1992). The ODB is governed by the rules and regulations put in place by 
the MOHLTC which is the “structure” in the interplay framework; those who are affected by the 
policies fall under “process” and “ideas” which refers to the doctors, pharmacies, patients, the 
MOHTLC, and drug companies. The following discussion is presented while keeping in mind all 
those involved in the interplay framework, in other words, all those affected or influenced by the 
ODB program.   
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5.2 Views on the ODB Program 
 
 There were 10 primary care physicians who took part in the semi-structured interviews 
for this research project. Each primary care physician was asked the same questions and their 
responses to the questions helped to provide insight into the ODB program – its advantages, 
disadvantages, and areas which require improvement. Physicians talked about the policies 
surrounding the ODB program, the problems with these policies, and suggested ways to change 
the program to improve delivery of care and to help them make the right informed decisions 
when it comes to patient care. In this case, physicians questioned the process used to decide what 
drugs make it to the formulary and which drugs get funded (as illustrated in Figure 2).  
 Every primary care physician was asked about their general views on the ODB program 
and some responses overlapped, while others varied. There were definite themes that were 
common such as the discussion around branded vs. generic medications, transparency of the 
program, education for primary care physicians, and other suggestions for improving the ODB 
program. All physicians began by stating that they are quite satisfied that a program such as the 
ODB exists and it allows seniors and those on social assistance the opportunity to receive drug 
coverage for their medication needs. Although the literature did not contain any studies that have 
been published on the ODB program specifically, there were studies that showed the importance 
drug coverage has for the health of Canadians (Canadian Institute for Health Information, 2011; 
Irvine, Ferguson & Cackett, 2005). When recognizing the health outcomes, those who are 
eligible for public drug coverage are more likely to follow a medication regimen compared to 
those who do not have any drug coverage. Physicians also noticed that those who are 65 and 
older or who are on social assistance have better compliance to the recommended drug treatment 
regimen than those who do not have any drug coverage at all.   
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5.3 Generic vs. Branded Medications. 
 
 The literature has shown that there is a lot of controversy about generic drug costs in 
Canada (Competition Bureau Canada, 2007; Skinner & Rovere, 2008; Law, Ystma & Morgan, 
2011; Demers et al., 2008; CIHI, 2002; CIHI 2012; McMahon, Morgan and Mitton, 2006). 
Although the primary care physicians were more concerned with effectiveness rather than cost 
with respect to the branded vs. generic drug debate, there is a great need for more research with 
generic drug products. The key informants requested that there be more evidence-based studies 
conducted and that they be informed of the evidence prior to a generic form of a medication 
being listed on the ODB formulary. They did confess that there are some patients who strictly 
request branded medications; however, there are some who simply cannot handle the generic 
makeup of the medications (Competition Bureau Canada, 2007; Skinner & Rovere, 2008; CIHI, 
2012; Law, Ystma & Morgan, 2011).  
According to Health Canada`s standards, a generic drug may be no less than 80%, or no 
more than 125% of the brand name (CADTH, 2012). However, there are some patients who react 
adversely to the differences in ingredients between the two drugs. The literature also suggests 
that, within Canada, there is not a very large difference in terms of cost between the generic and 
branded drugs. Davidoff (2001) wrote an editorial arguing that “cost effectiveness” in terms of 
health care does not necessarily mean that money is being saved. The argument still stands that it 
may not be worthwhile for the MOHLTC to provide coverage for generic drugs when it is 
evident that the generic drug is not much cheaper than the branded one. The results of this study 
showed that the argument between generic and branded drugs remains and that there are some 
physicians who do not have a problem prescribing generic drugs. However, there are some who 
have many concerns. There are some primary care physicians who showed concern about patient 
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safety with the use of generic products as opposed to branded ones (Kesselheim et al., 2008). 
More transparency in the decision making process of listing and de-listing drugs, as well as 
providing evidence-based literature to support these decisions will help to close the gap between 
the differences in opinion about generic drug use and branded drug use.  
5.4 Importance of Transparency/Increasing Education for Physicians . 
 
For the most part, physicians were quite content that a program such as the ODB exists; 
however, some suggested that it is not “the best program out there.” Several key informants 
mentioned that they would like to be a part of the decision making process when it comes to 
policy decisions in terms of the ODB program. The key informants would also like to see more 
transparency in the rules and regulations that govern the program. Several of them were not sure 
if there were some physicians who were part of the policy decision making process, although 
according to the MOLHTC, there are some physicians on the committee. With that said, the 
MOHLTC should make efforts to deliver information more clearly to physicians about the 
policies surrounding the ODB program. This leads to several of the primary care physicians’ 
requests to be more educated, not only with the MOHLTC and ODB program policies, but with 
changes that occur within the program, as well as any new evidence based decisions that are 
made within the ODB program.  
Zwarenstein et al. (2007) proposed that there are gaps between what physicians do in 
their clinical work, and what the research evidence states should be happening in practice. The 
LU codes were designed for a reason: however, they do not seem to be carrying out their initial 
purpose which is essentially to “limit” the use and prescription of that particular medication to 
ensure that the patients who will benefit most from the drug are using it. It seems as though 
74 
 
physicians are finding ways around the policies and procedures surrounding the LU codes and 
therefore the LU codes are not being used for their intended purpose. This is an example of an 
ineffective policy which can relate back to problems in the “process” as outlined in Figure 2.  
The primary care physicians had more concerns with the EAP, also referred to as the 
Section 8 requests. Just like the LU codes, there is minimal information in the literature about the 
EAP program, It is not very clear how effective the EAP is, and how often it is reviewed. Several 
physicians expressed that “They need to remove section 8.” Similar to the case with the LU 
codes, some primary care physicians indicated that they do not have a problem with the EAP 
program; however, there were more physicians who expressed difficulties with the EAP. Their 
main concern was the timely review of the EAP requests which is also concern with the 
“process” also outlined in Figure 2. Some physicians also stated that they have had little to no 
success with the EAP and that they no longer use the program. This may explain why none of the 
primary care physicians mentioned the Transparent Drug System for Patients Act (TDSPA). 
There is no supporting data in the literature regarding the EAP or the TDSPA. However the 
Multiple Sclerosis Society of Canada participated in the Government of Ontario’s drug strategy 
review in 2003 and they concluded that there were many areas within drug coverage policies that 
needed improvement. The MS Society of Canada had some concerns with the ODB program as 
four of the most effective MS treatments are not found on the ODB formulary and an EAP 
request must be sent to the MOHLTC in order to request coverage for those medications 
(Multiple Sclerosis Society of Canada, 2003). Currently, the MS Society of Canada website has 
updated their information and lists a number of medications that are not covered under ODB and 
patients who qualify for ODB coverage must have their physician fill out an EAP form (section 8 
form) and submit it to the MOHLTC. The content from the MS Society of Canada was the only 
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available information in the literature that discussed the EAP. There is a need for further research 
in this area, especially for certain vulnerable patients in the population who may not be able to 
receive drug coverage for illnesses such as MS. A major concern with this is that patients may 
not be receiving the best quality of care. What is also of concern is that McMahon, Morgan and 
Mitton (2006) conducted a study and concluded that drug benefit providers around the world are 
investigating more restrictions on drug coverage policies as cost-effectiveness has become more 
important than clinical effectiveness and quality of life. Here, the problem lies within the 
“process” as illustrated in Figure 2. The concern is that one of the main goals of healthcare 
delivery is for the betterment of the patient. If we are beginning to move more towards the 
cheaper option for treatment rather than the best quality of care, then our healthcare system is not 
improving. 
At the same time as the McMahon study was published, the TDSPA was implemented 
(2006) in an effort to improve the public drug system in Ontario. Specific changes were expected 
to occur when the act was implemented; however, this research did not find any evidence that 
these changes had been implemented. One of the goals of the act was to eliminate the Section 8 
process (MOHLTC, 2012). Although this act has been implemented for more than six years, 
none of the primary care physicians mentioned anything about this act during the interviews. In 
fact, all of the primary care physicians referred to the Section 8 process still as a form that needs 
to be completed. The “process” as illustrated in Figure 2 is being compromised. The policies that 
have been set in place to improve the Section 8 process are not working very well. The 
MOHLTC does not clarify on the website the process for the new and improved Section 8 
process. When the researcher called the MOHLTC to request clarification on the Section 8 
process, it was confirmed that primary care physicians are aware that they no longer need to fill 
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out the forms. This is an example where the “process” is being compromised. They are supposed 
to be able to call the MOHLTC and submit a request for coverage for a specific medication for a 
patient on the phone, and receive approval or disapproval of the request in a timely manner. It is 
evident that not all primary care physicians were made aware of this change that occurred more 
than six years ago. This was also evident when a pharmacist was approached and also was not 
clear on the TDSPA. This also provides more support for the need for improved education from 
the MOHLTC to the frontline healthcare providers, as well as for greater transparency. The 
primary care physicians are unaware of these changes; therefore, neither they nor their patients 
are benefitting from these changes. This is an example that affects not only the “process” but the 
“structure” as well, as illustrated in Figure 2. 
5.5 Suggestions/Improvements. 
 
 The results of this study have revealed areas for improvement and change within the 
ODB program. The rules and regulations that govern the ODB program need to be revised and 
any changes need to be clearly implemented with education to ensure the frontline workers are 
aware of and following the changes to benefit the patients.  
5.5.1 Limitations for Prescribing Physicians 
 
 Several physicians expressed their concerns with the limitations they encounter when 
writing certain prescriptions. In Laupacis’ editorial (2002), he stated that physicians find some of 
the policies surrounding the ODB program to be limiting for prescribing physicians. The LU 
codes specifically were what Laupacis (2002) was referring to. Some key informants described 
their frustration with the LU codes and described how they feel they are unnecessary; however, 
some key stakeholders did not elaborate about any difficulties with the LU codes. It was 
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noticeable that some physicians were able to learn how the system works and were able to 
“follow” the rules and regulations surrounding the LU products with no problems at all. One 
unknown is how much time and effort is undertaken to manage the LU system by MOHLTC and 
healthcare workers.  Although there is a noticeable struggle with the LU codes, currently there 
are few known studies in the literature other than this one that discusses the LU codes and their 
possible limitations to prescribing physicians and how the LU codes may be affecting delivery of 
care to patients. Therefore, Laupacis (2002) argues that further research in this area is needed 
and the results of this study support this statement and his point of view. 
5.5.2 The De-listing of Drugs from the Formulary. 
 
 The literature search suggests that there is a lack of evidence about the ODB program, as 
well as drug coverage policies in general. Primary care physicians expressed concern about the 
de-listing of drugs from the formulary without being informed. Information in the literature 
supports the idea that family physicians are affected by decisions made by policy makers. 
Godwin et al. (1996) conducted a study where they reviewed the delisting of drugs from the 
ODB formulary and how that affected the attitudes of prescribing physicians in Kingston, 
Ontario. Although Godwin et al. (1996) found that physicians were negatively affected by the 
de-listing of drugs, their review also concluded that there is not any information in the literature 
about the de-listing of drugs from the drug formulary in Ontario. This suggests that more 
physicians should be involved in the decision making process in terms of the ODB program, 
especially because the elderly in North America are the fastest growing population and have the 
highest rates of healthcare use (Suri & Clarke, 2009). Although physicians were concerned with 
the de-listing of drugs from the formulary without being informed, the information is available to 
the public through the MOHLTC website. There are a number of documents listed that describe 
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the changes that have been implemented within the ODB formulary (MOHLTC, 2013). These 
documents are fairly long, and most of them are more than 200 pages in length. The 
recommendation from the Committee to Evaluate Drugs (CED) is also available along with the 
Executive Officer’s final decision. Although the information is available to physicians, it is 
evident that they are not accessing the information. There are obvious gaps in communication 
amongst physicians and the MOHLTC. This is an example of a problem with the “process” 
associated with the ODB program as illustrated in Figure 2. The MOHLTC is recognized for 
providing the information to the public; however, the physicians are not taking advantage of the 
availability of the information. Improving communication and educating physicians about the 
changes that occur over time to the ODB program is a recommendation that can be formulated 
from the results of this study to improve the delivery of services offered by the ODB program. 
 There was some concern with eligibility criteria of the program. Although all seniors 65 
and older are eligible for coverage with the ODB program, there is some concern with eligibility 
prior to the age of 65. A few primary care physicians confirmed that they believe that 65 may not 
be the most appropriate cut off age for eligibility for the ODB program. Future evaluation of the 
appropriate initiation age may help to improve health outcomes amongst the elderly population. 
This is an example of the “process” as well as the “structure.” Physicians are questioning the 
“process” and “structure” as illustrated in Figure 2. 
5.6 Future Implications 
 
 The purpose of this research was to study the ODB program from the physicians’ 
perspectives. This study not only helped outline the advantages and disadvantages associated 
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with the ODB program, but also identified areas that can be undertaken in future research 
projects.  
5.6.1 Universal Pharmacare. 
 
 Future research implications include comparing the different drug coverage programs 
from province to province. This study only included interviewing physicians specifically about 
the ODB program; however, key informants identified that it would be worthwhile to assess the 
adoption of a countrywide pharmacare program (Romanow, 2002). Having a universal 
pharmacare program could save the healthcare system a significant amount of money according 
to several researchers (Law, Ystma & Morgan, 2011; Demers et al., 2008; Romanow, 2002; 
Clement et al., 2009; Gagnon, 2010). A second part to this study would be to compare how often 
the drug coverage programs are used across the provinces and territories in Canada, and compare 
their successes to the provinces and territories that do not have a drug coverage program. 
 Concentrating on cost containment for future research projects is also essential when 
determining if a universal pharmacare program is more beneficial for Canada. Evaluating several 
documents such as progress reports from the governments of each province and territory will 
provide a clearer idea on how much money is spent on drug coverage programs and how they 
can be improved. 
 Lastly, expanding research on generic drug products is also important. Physicians showed 
some concern about generic drugs in comparison to their branded drug form. Physicians 
requested that there should be more research conducted on generic drug products before they are 
allowed to enter the market. Also, researching drug prices across the nation, as well as 
internationally, could provide some insight as to why the cost of drugs is much higher in Canada 
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compared to other parts of the world. The cost of generic drugs in Canada is decreasing however, 
more research needs to be done to ensure that these costs continue to decrease so that the drug 
coverage programs can continue to improve.  
5.6.2 Expanding this Research.  
 
 This research only included family physicians in a medical clinic in a small town in 
Ontario. Future research studies can include specialists in the field, as well as pharmacists, 
nurses, policy makers, and patients. By including more physicians, nurses, pharmacists, policy 
makers, and patients in a study evaluating the ODB program, more insight will be attained about 
the ODB program because a greater number of and more diverse key informants will be included 
in the study. This is based on the theoretical framework illustrated in Figure 2. The significance 
of this framework is that it illustrates the key stakeholders who are affected by the policy 
decisions regarding the ODB program. Each person will bring new information to light regarding 
the ODB program. Evaluating the ODB program from different perspectives will also provide a 
deeper understanding of the areas that need improvement to improve delivery of care. The results 
of a study such as this may help to identify the importance of including physicians, pharmacists, 
policy makers, and patients when making policy decisions and when developing and improving a 




The document review was also limited due to the fact that there was not a lot of 
information available in the literature regarding the ODB program. Another limitation is the 
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approach chosen which was to examine the ODB program from primary care physicians’ 
perspectives and not from the patients’ or policy makers’ perspectives.  
 Furthermore, I must make the readers aware of the levels of bias that I brought to the 
research. With a background working in a doctor’s office for several years, seeing firsthand how 
some of the policies work, or do not work for that matter, have influenced the conclusions and 
findings that I have gathered. The conclusions I will have were affected by my perspectives as a 
former administrative assistant for the past nine years. Another limitation is the fact that the data 
was interpreted by one person only to identify the findings and thus make recommendations.  
 Although I am confident in my scoping review and searching methods, further limitations 
include those from my scoping review. I had difficulty finding papers that have studied the ODB 
program and its flaws and weaknesses. My literature search may have been flawed since there 
are not very many research papers available in the literature about the limitations of the ODB 
program, my search terms may not have been able to target all the important papers regarding 
this topic. Another limitation that I must be aware of, is time restraints. Lastly, since some 
primary care physicians did not feel comfortable being audiotaped, notes were taken by the 
interviewer instead. The scoping review was limited to English only. This may limit my findings 
as it may potentially disallow the discovery of different perspectives of the ODB program. This 
may yield some limitations as transcription of interviews not audio-recorded, are not as detailed 
as transcribed interviews. Reassurance of the appropriate transcription of non-audio-recorded 




 Another limitation lies in the methodology. The case study approach does work with this 
type of study however a case study is more credible when data is collected from numerous 
sources such as one-on-one interviews, focus group interviews, observation and documentation. 
This study only used one data collection method; semi-structured interviews with primary care 
physicians (Yin, 2003). However this is a first step to better understand the views of prescribing 




 Studying the ODB program provided insight on the importance of evaluating a program 
such as the ODB, as well as the importance of including physicians when making policy based 
decisions in healthcare. Although it was revealed that there were many advantages associated 
with the ODB program, there are areas that need improvement. Physicians requested that there 
should be more transparency with the rules and regulations that make up the program and 
ongoing education and follow up to ensure the program is working the way it was intended. 
Furthermore, the implementation of a national pharmacare program in Canada has the potential 
to reduce costs and increase access to medications. Additional results from this study suggest 
that certain challenges exist in obtaining the most appropriate drugs for individual patients with 
the limitations of the ODB program. Challenges also exist that impact the quality of care and 
costs associated with procedural requirements. 
 Although there seems to be routine information sharing between the MOHLTC and the 
primary care physicians, the communication that exists is not as efficient as it should be. It is 
evident that physicians are not all informed about some of the policies and changes implemented 
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in the ODB program. To address this form of miscommunication, we recommend that the 
MOHLTC examine this process and modify how they deliver their information. Establishing 
routine seminars or presentations should be offered to groups of primary care physicians twice a 







Ministry of Health 
and Long-Term Care 
 
Exceptional Access Program Branch 
5700 Yonge Street 3
rd
 floor 
Toronto ON  M2M 4K5 
Request for an Unlisted Drug Product 
Exceptional Access Program (EAP) 
Please fax completed form and/or any additional relevant information to 416 327–7526 or toll–free 1 866 811–9908; or send to Exceptional Access 
Program Branch (EAPB), 3
rd 
floor, 5700 Yonge Street, Toronto ON  M2M 4K5. For copies of this and other EAP forms, please visit 
http://www.health.gov.on.ca/english/public/forms/form_menus/odb_fm.html 
The Ministry of Health and Long-Term Care (the “ministry”) considers requests for coverage of drug products not listed in the Ontario Drug Benefit Formulary under Section 16 of the  
Ontario Drug Benefit Act. This form is intended to facilitate requests for drugs under the Exceptional Access Program. The ministry may request additional documentation to support the 
request.  




Section 1 – Prescriber Information 
First name 
      
Initial 
    
Last name 
      
Mailing Address 
 Street no. 
      
Street name 
      
City 
      
Postal code 
      
Fax no. 
(       )       
Telephone no. 
(        )       
Section 2 – Patient Information 
First name 
      
Initial 
    
Last name 
      
Health Number 
       
Date of birth (yyyy/mm/dd) 
      
 New request   Renewal of existing EAP approval (specify EAP#)       –
  
      
Section 3 – Drug Requested 
Requested drug product 
      
DIN 
      
Strength / Dosage form 
      
Frequency of administration 
      
Expected start date 
      
Duration of therapy 
      
Section 4 – Diagnosis and Reason for Use 
Diagnosis for which the drug is requested: 
      
Reason for use over formulary alternatives: 
      
If the patient is currently taking the requested product, please provide start date & objective evidence of its efficacy:  
      
Section 5 – Current and / or Previous Medications 
a)  Please provide details of alternatives (listed drugs and/or non-drug therapy) tried for this condition: 
Name of drug 
(indicate if currently or previously taken) 
Dosage 
Approximate 
 timeframe of therapy Reason(s) why formulary alternatives are not appropriate 
      
 current 
 previous 
                  
      
 current 
 previous 
                  
      
 current 
 previous 
                  
      
 current 
 previous 
                  
b) Provide patient’s concomitant drug therapies for other conditions: 
      
Section 6 – Clinical Information 
Please provide relevant medical data (e.g. culture and sensitivity reports, serum drug levels, laboratory results):  
      
The information on this form is collected under the authority of the Personal Health Information Protection Act, 2004, S.O. 2004, c.3, Sched. A (PHIPA) and Section 13 of the Ontario 
Drug Benefit Act, R.S.O. 1990c.O.10 and will be used in accordance with PHIPA, as set out in the Ministry of Health and Long–Term Care “Statement of Information Practices”, which 
may be accessed at www.health.gov.on.ca.  If you have any questions about the collection or use of this information, call the Ontario Drug Benefit (ODB) Help Desk at 1 800 668–6641 
or contact the Director, Exceptional Access Program Branch (EAPB), Ministry of Health and Long-Term Care, 3rd floor, 5700 Yonge St., Toronto ON  M2M 4K5. 
Prescriber signature (mandatory) 
 
CPSO number 
      
Date 
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Title of Research Project:  






Faculty of Health Sciences 
University of Ontario Institute of Technology 
2000 Simcoe St. North 
Oshawa, ON; L1H 7K4 
(905) 243-9897 
rima.karam@uoit.ca 
Faculty Supervisor:  
Brenda J. Gamble, Ph.D. 
Faculty of Health Sciences 
Consent Form 
R E S E A R C H  E T H I C S  B O A R D  
O F F I C E  O F  R E S E A R C H  S E R V I C E S  




University of Ontario Institute of Technology 
2000 Simcoe St. North 
Oshawa, ON; L1H 7K4 
(905) 721-8668, ext. 2934 
brenda.gamble@uoit.ca 
 
Purpose of the Research: 
 
The purpose of this study will aim to a) explore and analyze the strengths and weaknesses 
of the Ontario Drug Benefit (ODB) program. b) to document how the ODB influence physician 
prescribing behaviour for Ontarians aged 65 and older who qualify for coverage under the ODB 
program. As part of this study, we will be conducting one on one interviews with physicians.  
 
 
Description of the Research: 
 
  We plan to collect information from physicians through individual in-depth interviews conducted 
in person. You are being asked to participate in one individual interview conducted with the principal 
investigator. We will be asking you to share your views about the Ontario Drug Benefit Program (ODB). 
The interview will take approximately 30 to 60 minutes. 
  We will contact you either by e-mail or phone, to set up the day and time of the interview 
according to your preference. The interviews will be audio-taped and transcribed. If you do not wish to 
be audio-taped, the principal investigator will take notes throughout the interview instead. Only the 
principal investigator will be able to identify you. The interviewer and transcriber is the same person 
(Rima Karam). 
 
  Once the interview has been completed, the audio-tape will be kept in a locked, safe place in Dr. 
Gamble’s office and your name will not be marked on either the tape or any paper material. You will not 






There are no known harms that we are aware of that are associated with participation in this study but 
there may be harms that we do not know about. 
 
Potential Discomforts or Inconvenience: 
 
  Sometimes people involved in discussions like these feel stress and anxiety. If this 
happens to you, you may stop the interview at any time. In addition, there is no guarantee that 
the proposed research will result in any change specific to the policies or procedures in the 





  Participants will have the ability to make their views known about the Ontario Drug 
Benefit Program (ODB). This study will add to the knowledge of the ODB program and the need 





 The data is initially not anonymous, however once the audiotapes are transcribed, they 
wll be permanently deleted. All identifying information will be removed from the data collected 
prior to analysis of the data and release of its findings. Once the audiotapes have been 
transcribed, they will be permanently deleted and no identifying information will be included in 
the transcripts. The principal investigator; Rima Karam, will have primary access to the data and 
any identifying factors. Dr. Gamble will have access to the data but will not have access to any 
identifying factors, and neither will the rest of the research team. Your privacy shall be 
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respected. No information about your identity will be shared or published without your 




This project has been approved by the Research Ethics Board at UOIT (REB file# 12-
023). Your participation in the interview is purely voluntary and as such, you may choose to 
refuse to answer any question you wish and you may leave at any time. You are not waiving 
your legal rights by participating in this study. However, once information is written 
down/audiotaped, it can no longer be withdrawn/erased due to the anonymity of the interview. 
 
 
Conflict of Interest: 
 
  The Principal Investigator; Rima Karam, may have some conflict of interest as she may end up 
interviewing physicians she has worked with before. 
 
 
Consent to Participate:   
By signing this form, I agree that: 
 
1. “I have read the consent form and understand the study being described”; 
2. “I have had an opportunity to ask questions and my questions have been 
answered.  I am free to ask questions about the study in the future.”;  
3. “I freely consent to participate in the research study, understanding that I may 
discontinue participation at any time without penalty. A copy of this Consent Form has 
been given to me for my records.”  
I understand that I have the right not to take part in the study and the right to stop at any time.  
 4) I am free now, and in the future, to ask questions about the study.   
 5) I understand that no information about who I am will be given to anyone or be published 
without first asking my permission.  




6) I also agree to be audiotaped during this study.  These tapes from this interview 
session will be used to assist with transcription of important information that will be 
discussed in the written thesis. If I do not agree to be audiotaped, the principal 
investigator will take notes throughout the interview instead. 
7) I am free now, and in the future, to ask questions about the taping. 
8) I have been told that my transcripts will be kept private.  You will give no one any 
information about me, unless the law requires you to. 
9) I understand that no information about me (including these tapes) will be given to 
anyone or be published without first asking my permission. 
10) I have read and understood this consent form. I agree, or consent, to take part in this 




(Name of Participant)     (Date) 
 
___________________________________   _______________________________ 





















July 30, 2012 
 
Rima karam 
2000 Simcoe St. N 
Oshawa, ON L1H 7K4 
 
Hello Dr. _____________________ 
 
Physicians’ Perspectives on the Ontario Drug Benefit Program (ODB). 
 
  You are being invited for an interview to provide a deeper understanding of the limitations of the 
Ontario Drug Benefit Program (ODB). This interview will be approximately 30 to 60 minutes in length 
and tape recorded. You will be asked about your views on the Ontario Drug Benefit Program (ODB). 
The purpose of this study will aim to a) explore and analyze the strengths and weaknesses 
of the Ontario Drug Benefit (ODB) program. b) to document how the ODB impacts physician 
prescribing behaviour for Ontarians aged 65 and older who qualify for coverage under the ODB 
program. As part of this study, we will be conducting one on one interviews with physicians.  
  Participants will have the ability to make their views known about the Ontario Drug Benefit 
Program (ODB). This study will add to the knowledge of the ODB program and the need for change and 
improvement. The expected duration for this research project is approximately August 2012 to 
December 2013. 
  The interview will be audiotaped. These tapes will be transcribed for analysis and deleted at the 
end of transcription. All data obtained during all parts of this study will be kept confidential and 
anonymous. You are welcome to withdraw from the study at any point of the project.  
  If you are interested in participating in this study, please e-mail me or contact me by phone.  
With Thanks, 
Rima Karam 







If you have any pertinent questions about your rights as a research participant, please contact the 



























Physicians’ Perspectives on the Ontario Drug Benefit Program (ODB). 
Key Informant Interviews Script – What will be said at the beginning of the interview 
 
Hello Dr. ___________________, 
Thank you for taking part in our research project studying the “Physicians’ Perspectives on the 
Ontario Drug Benefit Program (ODB).” 
As part of this research study, you were invited for a key informant interview. The purpose of 
this interview is to obtain your views on the Ontario Drug Benefit Program (ODB) as a 
prescribing physician. 
The interview will take approximately 30 to 60 minutes in length. You will be asked about your 
views on the ODB program, Limited Use Codes (LU) and Section 8 requests, and how they may 
influence your prescription ordering behaviour. 
During this interview, I kindly ask that you refrain from using the names of, or any identifying 
information of your colleagues, patients, other individuals or institutions. 
The interviews will be audiotaped using a digital recorder and will be transcribed for data 
analysis. The interviews will be coded and all identifying information will be removed. The code 
sheet will be kept in a separate file from the data and locked in a secure filing cabinet. The data 
and consent forms will be kept in a locked file drawer in Dr. Gamble’s office (supervisor). All 
data will be kept confidential and anonymous. 
If, during this interview, you feel uncomfortable with a question, you have the option of avoiding 
it and may do so by indicating your choice to the interviewer. If you would like to discontinue 
your participation in the interview, you may do so at any time. Your consent form and any data 
collected prior to your withdrawal will be destroyed at the time of the withdrawal. 
Once again, I thank you very much for your participation. Your contribution will help inform 
about the Ontario Drug Benefit Program in the healthcare sector in Ontario. 
 
 






Physicians’ Perspectives on the Ontario Drug Benefit Program (ODB). 
Key Informant Interviews Script – What will be said at the end of the interview 
 
Dear Physician ________________________, 
 
Thank you for participating in this study. Your time and patience are greatly appreciated 
and your contribution to this research is invaluable. 
 
I will follow up with you on the results of the study once it is completed via a letter. The 
principal investigator will be the only one who will have access to the follow-up letter to ensure 
confidentiality.  
 

















Table 2: Audit Trail of Interview Themes 
 Direct Quotes 
General 
opinions of the 
ODB: 
- I don’t think it’s the best program out there 
- Very limiting for prescribing medication 
- It is a good program – it cost government a lot. ODB is a good 
program but the section 8 and de-listing of drugs and writing 
prescriptions differently to get coverage is what bothers me the most. 
If it is covered, it should be covered either way no matter how I write 
the prescription. 
- So for myself, being an international medical graduate, it is completely 
foreign. What I know about the program is what I’ve learned in 
practice and in the office and it does appear at times cumbersome. And 
the complete extent and the workings of it, I may be lacking in 
complete understanding of it, but what I know if what I have 
experiences at the office. 
- Well for myself, just having a program like that was foreign because 
coming from a third world country, we don’t have social support, it is 
a great idea and I think it is an excellent idea, it is a very socially 
responsible program so I appreciate having such a thing for the 
vulnerable population. Where I see a big benefit sometimes is in the 
older population, just before they turn 65, prior to 65, they can’t afford 
second prevention for diabetes or post MI. they don’t have the money 
to pay for that because normally they will be on 4 or 5 drugs like they 
will be on an aspirin, a statin and an ace and beta blocker and a 
diabetic medication and as soon as they turn 65, the compliance 
improves because now they have access to those medications so that’s 
where I see a benefit for my patients. 
- I’ve experienced better compliance after 65 compared to prior to 65. 
- It’s an excellent program. It’s an essential program. The biggest cost 
to healthcare I think in Ontario is not the cost for paying for doctors, it 
is therapies and hospital care and their therapies; drugs and so forth 
and for those people who do not have insurance plans, without an 
ODB, they wouldn’t get anything. And that is a big problem. Because 
you can go to the best doctor around, still not have to see a bill from 
that individual but if he writes you a prescription for a medication for 
$1000 a month and you can’t pay for it, you walk out of the office and 




throw it away. So it is an essential program. And I think that’s one of 
things that is very very important to all of us but I think it 
encompasses probably two things; 1. Is for  looking after those 
individuals who can’t pay for therapy which is very very important, 
the rest of the society like anybody else who has got health insurance, 
or extended healthcare benefits they always pick up the cost of drugs, 
pick up the cost of physio and so forth. But for those individuals that 
can’t afford those types of programs, being able to get medicines of 
any sort, even if they are pre-registered under the ODB plan, it is an 
essential thing. Otherwise all the therapies that we can suggest mostly 
go out the window. Particularly as a general practitioner because most 
of my job is talk therapy and prescriptions. Now, you can still get your 
appendix taken out even if you don’t have the money for the 
antibiotics, but if you needed the antibiotics on discharge from the 
hospital and you can’t pay for them then you are going to be out of 
luck, or painkillers – very simple kinds of therapies. So the program is 
essential and I think for the most part, is managed very, very well.  
- I really have not had very much of a problem with it ever when 
somebody comes in with drug cards. Now the business you run into is 
when you need to prescribe someone something that isn’t on the ODB 
list and then you have to decide yourself just how much of a fight you 
are going to put up with it because there are certainly products that are 
as equal as whatever you have chosen and certainly in lots of cases a 
whole lot cheaper. And that’s why the ODB – that’s their 
administration, they look after this drug, this drug, this drug and pick 
the one that’s going to be the cheapest if they are all going to be totally 
equivalent. I think im all in favour, I think it is an essential program 
and for the most part it is very well managed I don’t have much of a 
problem with it. 
- I haven’t given a whole lot of thought to that and the reason is that the 
program works very, very, very well. The whole point to me would be 
that the people who need those therapies can get them and at the end 
of the day that’s all to me that really matters, I’m not a big policy guy. 
I’ll work within your framework and I’ll cheat if I have to but I’m not 
the guy that wants to set and make policies so for now I’ll live with 
that. But it does work well enough for me that I don’t have a big 
problem with it. Now, it would be very interesting just to see what the 
patients’ aspect on this program is, you know, they might have a 
completely different point of view when all of a sudden you know they 
go to the pharmacy and the pharmacy says well you are three days 
early, you have to come back three days from now. But that would 
make the pharmacists a bit of a hard ass and I don’t know many of 
them that are most of them are pretty decent people too. And if they 
see somebody who is going to be short a few days, they will say ok we 
will sort it out but make sure you go back and tell your doctor he has 
to write the next prescription for a few days earlier to cover you when 
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you come in early next month. And again it all comes down to the 
compassion people in healthcare field have to have for the people that 
are requiring the healthcare. They might have a different opinion 
though, you know, but I think anybody who needs an ODB card for 
example, particularly a young person who is supposed to be out in the 
working world like all the rest of them, anybody can fall on hard 
times. And it’s really, really nice to know that that thing is off your 
mental plate if you had a kid that was sick or something, you are not 
going to have to worry about coming up with the 80 bucks for the 
antibiotics or whatever is costs. For the elderly, because they are the 
other group that are ODB covered – right everybody over 65, they are 
for the most part, very, very compliant with the advice the physician is 
going to give and if the physician says I think we should try this first, 
very seldom you get a rejection on that one, I don’t anyway. They will 
say ok fine, we will go with this and see what happens but they are 
willing to be very flexible and they will say ok if the government 
doesn’t pay for this, that’s fine, but if they have been on something, 
and it has worked for them, they are resistant to change. And that’s 
why when they click over from 64 to 65, there is no grandfather clause 
in there that says ok you have been on this nice drug because your 
insurance company has picked up the tab until you were 65, now the 
government picks up the tab and they don’t pay for whatever you 
want. There might be some proviso in there, that they can still get at 
least the cost of what the generic drug would have been paid for, and 
they will pick up the tab for the balance of that drug. But I’m not sure 
if they can do that. I think it’s an all or nothing thing. That might also 
be something to investigate as whether or not – because the 
government will say we are going to pay for this drug, but this drug 
here, if you want it, you pick up the entire tab for, that’s not really fair. 
A person might be willing to come up with the difference. But if they 
are supposed to be their particular drug paid for to some degree, they 
would appreciate that being the case, even if they want the drug that 
costs more. You know, the government will pick up the first 60 bucks, 
I’ll pay the next $40. But I don’t want to have to pay the $100.00, and 
a lot of times people will also – again, depending on financial 
situations, might bite the bullet and go with the generic one, but then 
they will complain about that. 
- I guess it makes available to a large majority of our citizens who don’t 
have the means to afford medications, it makes medications easily 
available to them for the management of their health issues and 
chronic diseases so that’s probably the biggest single benefit as I’m 
sure you and I will benefit one day! 
- again, overall, I still am a big supporter, we arbitrarily make 65 the cut 
off, I know people are on social assistance, so there is an arbitrariness 
to it because we don’t suddenly need it at 65, I know they tried to align 
it with our retirement age, which is now changing, so not withstanding 
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– there are some arbitrary features, but overall I am still happy. So 
long they maintain a policy of doing a good job of evaluating the 
evidence behind the use of medication and they apply those criteria, 
we should be fine. The biggest challenge is the affordability of the 
strategy in the long term. You know as we have a population that is 
aging, a larger percentage of elderly, our use of this system will keep 
growing and what does that mean for the system as a whole? So I 
guess we will find out in time. For the moment, as it is, it certainly 
goes a long way to help me and my ability to manage my patients’ 
illnesses.  
- Good question. My experience would be mainly prescribing the 
medication covered by the program to patients, and I guess initially 
when I started, it was a bit difficult because most medications that I 
was used to were not covered by the program but as time has gone on, 
I kind of have an idea of the medications covered by ODB so I’m not 
having that problem with the pharmacy returning the prescription and 
saying this is not covered. On the positive aspect, they do a pretty 
good job to at least cover most medications, they may not be the best, 
they may not be the newest out there, but I assure the patients do have 
what they need. So it has been positive in a way and negative in a way, 
in the sense that I want more, but at least I have something. 
- I find the Ontario Drug Benefit program is used by the majority of 
patients that I see because the majority of patients that I see are 
elderly…and usually the poorer the patient is, the more medical 
problems they have, and so again, I see a lot of patients who are poor 
who are on the Ontario Drug Benefit Program, but they are called 
trillium for those who are low wage order, and on social assistance 
who are on ODB. So in terms of the percentage of patients that are on 
ODB, it is a high percentage.  
- In ODB’s mind, medications are not on their formulary because they 
have shown to have little benefit or little efficacy in treating particular 
illnesses, and some of these illnesses are nonsense illnesses, not to say 
they are not legitimate illnesses, but IBS is a diagnosis of exclusion, 
meaning there is nothing else you can find for a cause for abdominal 
pain, diarrhea, constipation, is considered IBS, those are a cluster of 
symptoms that give you that diagnosis. But again, the good news of 
the diagnosis of IBS, is that it is not going to affect the long-term, 
length of life, or risk of death or anything like that, but it is more how 
uncomfortable patient is and QOL that they have as a result of that 
illness, so those kinds of things, ODB doesn’t have good treatment for, 
or has delisted some treatments and it affects people’s qualities of life, 
and that’s more concerning in a lot of these people who need these 
medications are elderly, are poor, they don’t have money to get certain 
treatments outside ODB benefits and they don’t have the resource to 
work or get money in order to buy the treatments that are helpful for 
them given the QOL because the QOL is so bad, so it is kind of a 
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vicious cycle like that. 
- Diabetes medication is not covered. I’m not even sure the lancets – 
maybe the strips or the lancets are covered, but I’m not sure. So that 
would be something that could be included given the epidemic of 
diabetes. I imagine it is due to cost. 
- It is a big list of medications, I think I do like the Trillium Drug 
program, because it does allow people who aren’t older than 65 but 
have a high cost of medications relative to their income, gain access to 
medications, I haven’t looked at the application process for the 
program but I think it is based on your net income up to 4% of your 
net income, it may be a little complicated for patients to apply to it, but 







- I’m happy it covers Pradox in some cases, it is new and it has helped 
me better deliver healthcare to them 
- The positive thing is they cover medications in the same groups (i.e. 
GI meds, cardiovascular meds etc…) giving me a chance to choose 
best one for patients. Gives us opportunity to choose in case patient 
reacts to one of the medications that they are prescribed. 
- I am happy ODB is covering medications for patients who have no 
other access to medications 
- Ok, well first of all I guess I’m glad that it’s there because it is an 
important safety net for so many people who live in Ontario. So our 
senior population who do not have employment income coming in as 
well as people on social assistance, so people who are the working 
poor who do not have access to a drug plan, or to people who are 
unable to work because of disability so I think overall it is a good 
thing and I’m glad it is there. 
- I think it’s good, I think its ok. I mean a lot of people might think they 
are restrictive, they are not very open to taking in more medications 
but I think whatever they are doing, they are doing well in a sense that 
there are quite a number of medications that I see there that I’m 
surprised that they are there, they are approved a lot. Not as much as 
the medical healthcare professionals would want, and I think the 
reason is this – the bias is – there is this new medication in town, and 
everybody feels is the wonder drug and the first question they ask is 
what about coverage? And I think it is because of the medical system 
we have in Canada, the universal healthcare, where everything in 
quote is free so you expect coverage. The way they take time and put 
medications on the ODB makes sense to me. Let’s say we have six 
medications that you can use for blood pressure. I don’t think all six 
should be put on the ODB. Maybe two, maybe three, they are doing 
the same thing, So I like the way they streamline medications. There 
might be medications I don’t know about maybe cancer medications 
they need to put on it, but for my practice, what they have is good and 
I like the way they do it.  
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- That it exists! They have a good number of medications really, I don’t 
know how often they update it, I’m not sure and it is difficult, I would 
say it’s me, because I guess I should find a way to actually know the 
medications that are there, but there are so many of them, how am I 
supposed to put them in my head?! But the fact that the program exists 
and I can always find something for my patients is what I like about it. 
There is no medical problem that I have not found a medication for, it 
may not be the best, it may not be the newest or it may not be the one 
that has the most data out there but there is something for everybody 
on the program. That is what I like most about it.  
- In general, I’d been very happy with it, a large percentage of our 
patients who are on routine medications are often ODB candidate and 
by and large, most of the key medications that we prescribe are listed 
on the ODB so I have been happy with it.  
- I think for the most part, the ODB is fair, in terms of – it is evidenced 
based, they have tried to get the best evidence for which treatments 
work best for which diagnosis, there are some things that are clear – 
black and white, but there are a lot of things that are not clear and I 
think ODB has been very conservative in that and I think that is a good 
thing – being conservative in covering or not giving benefits to 
questionable treatments, so I do see ODB as being a very good 
program, given the fact that majority of patients that need it have no 
other way of getting the type of medications that they need. I think if 
we didn’t have ODB, didn’t have drug coverage for these patients, it 
will be like the states, you have to choose between eating one day and 
your medication which is horrible so absolutely, there are good things 
about the ODB program.  
- It’s been a positive one, except for trying new medications, recently 
approved medications or medications that are experimental; I don’t 
find it restricts me in prescribing the best medication for the patients 
who fall under the program. 
Disadvantages 




- I wish it would be covered for all patients not just for those who 
qualify for the LU code because I feel the cost of INR monitoring is 
high so if it is covered for all – patients don’t need to monitor blood 
work every week and it saves doctors’ time, nurses’ time, lab time, 
and money etc…. 
- That’s where you have to help me because I don’t understand the 
design completely. My biggest – the thing that I really suggest and 
that’s the problem with the whole of Canada that’s what I have 
experienced because I lived in Manitoba and then moved to Ontario, 
it’s like we live in 8 different countries in one country. That’s the 
biggest problem. I think if they can have their buying power 
consolidated and have a single formulary for the whole country, that 
can be cost containment. The way they do it now is very expensive. 
By fragmenting the programs, it is very expensive. They could have 
the basis of one buyer for the whole country and argue much, much 
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lower prices. And then be able to afford better benefits to the patients. 
My biggest advice to them would be consolidating all the programs. 
I’m a novice at this but I expect every province has its own program 
running a different criteria, so medical care in Canada is not really 
universal as they would like it but you can imagine if you had one 
buyer for the whole 30 million people rather than 7 million here and 
one million there, you can argue much better pricing, you would have 
better medication on the formulary you wouldn’t be able to afford 
otherwise.      
- It needs to be evidence based. Review the formulary more frequently 
than it is being reviewed from my experience, I mean I have only been 
here 6 years but I haven’t seen big changes in the formulary over the 
last six years, and medication that is already gone generic that 
shouldn’t be too costly, I can’t see on the program. I would feel more 
time to review, more evidence based, more discretion to the people 
that approve it they don’t need to follow strict guidelines, I’m sure 
when they get the request, they follow a set of boxes, and I don’t feel 
that is the best way to do it, it should be a knowledgeable person doing 
that because medicine is not “cookie cut” everyone has its own way of 
metabolizing medicine, everyone has a unique history etc… to tick the 
boxes is not the way to do it. 
- More timely review of the formulary, more discretion with use of the 
formulary, more evidence based application of the medications on the 
formulary I mean there are medications on there that I wouldn’t 
prescribe to anyone anymore just because there is not a lot of evidence 
of its safety, its efficacy compared to newer medications. I would use 
imovane again as an example – I wouldn’t want to prescribe 
tomazepan to anyone if I don’t have to, but with an older patient, when 
I have to prescribe benzo, in my experience, the imovane Is a cleaner 
drug, gives you better REM sleep and less addictive and you can use it 
ad hoc compared to the benzos. 
 





- (when asked since those prior to 65 can’t afford their medication, and thus 
will that yield their health to be worse?) Absolutely. I mean we have lots 
and lots of evidence out there that if you treat diabetes early on, you can 
prevent all the major vascular complications from strokes and heart 
attacks, the micro-vascular complications like kidney, eye, peripheral 
neuropathy, you can prevent all of that. It is good that you touched on that 
because if you don’t treat that early on, you are going to deal with that at 
65, you will start you secondary prevention later on, but you will have to 
deal with amputations, eye problems, laser, so is it cost effective not to be 
able to access that completely for my patients? Maybe not because the 
cost in the end, its over loaded now because now they get their injectable 
biologicals, their laser treatments, and those are very expensive that could 
have been prevented with cheap drugs initially. So it is costing more in the 
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end. It is great for 65 and over but what happens to patients before?    
- I like the fact that it is available to people who are most disadvantaged. 
- Eliminate the red tape when it comes to other or newer medications which 
also have strong supportive evidence don’t go down the paths of LU codes 
or section 8. I’m sure for very expensive medications; I can understand 
their reluctance to make those drugs easily accessible. I’m not sure what 
strategy they should employ to ensure that the drugs are used 
appropriately and as indicated, that is probably their big concerns, is that 
you know, people use drugs beyond their indication and when drugs are 
prescribed that way, it costs the system and we are not practicing evidence 
based medicine. So I’m not really sure how they would police that but 
certainly you know, if the evidence is there, I guess it would be helpful if 
they looked at other strategies beyond making it difficult to get the 
medication, so does it have to be red taped, or can there be an appropriate 
process that defines them and us that the patient is getting the medication 
for a medically acceptable reason and do it in a way that isn’t so 
challenging. That is probably harder than it sounds but that would 
certainly I think make it better for consumers and physicians. 
- I would think in isolated circumstances that might be true. But I would 
think that by and large, there are often enough options on the formulary to 
not create that kind of scenario on a regular basis but there can be 
incidence where there is that potential and then that becomes a question of 
what the physician in general will end up doing? Will they adjust their 
own strategy to try and get a drug covered or will they simply just tell the 
patient it is up to them. 
- You know, it always sounds nice in theory to make it more universal, in 
practice, I’m not really sure how feasible that is and how affordable that 
is. 
- I: when you say universal, do you mean throughout Canada, or …? 
- P: no I meant not restricting it to 65 and plus crowd. Right now people’s 
options are pay out of pocket, have a private insurer, or have ODB 
coverage, so if you are employed and you have a private insurer then yes 
your coverage is pretty good anyways, and I guess there are other options 
for folks who have very expensive medications, there is the trillium 
program, but I can’t say I understand how effective it is compared to ODB 
in terms of coverage, it is not as generous and it certainly creates much 
higher expectation on the patient maybe some hybrid would be 
appropriate in the long run because we also have a population of 65 and 
70 year olds who probably could afford to pay more than they do for their 
meds and as we are trying to create a cost containment strategy while 
maintaining the population health, I could see a scenario arising where 
there is a means test and what kind of subsidy you get for the medication 
depends on what your ability is to pay and afford and that might be more 



































- There is some data that is out there that shows that generic drugs are not 
as effective as the name brand drugs and some of the policy changes that 
need to happen is a more rigorous testing of generic drugs so that the bio 
equivalency, that the same effects occur with generic as the name brand 
drugs. So right now, I think they need 12 people in a study, in drawing 
blood levels, - so long that the blood levels achieve 80% of what the name 
brand drug is, the generic drug is considered bioequivalent – it’s not!! 
There is a huge variability in the generic drugs as a result of that, and 
having more stringent testing of generic drugs is important, second thing 
would be, I think I’m ok with having different processes for specific drugs 
that are on the drug benefit list, so long they give us some transparency 
about the rationale, because now it feels like it is very arbitrary for some 
of us, and education wise, it is important for ODB to be educators of 
prescribing habits, because they are the ones that have the formulary of 
what they cover and what they don’t cover, and to a certain degree they 
have very powerful influence in terms of what we use for particular 
indications, so having an education component, not just here is a blank list 
and give no reason behind this list as to why you should be using them, 
they have a real opportunity to make this an educational vehicle as well to 
help clinicians and providers not only make good clinical decisions, but 
the reasons behind those decisions. So for example, a new drug comes out, 
people will be asking is this on ODB, and it is under review, etc, so once a 
decision is made, even a quarterly newsletter that says we considered 
these medications and these medications are listed under EAP, LU, or not 
covered at all, that’s fine, that would give us an understanding about their 
decision making and give us clarity about our own clinical decision 
making when we are using these drugs, I think that would be helpful, they 
would have a very good audience since everybody uses ODB (all 
physicians). 
- I certainly appreciate the government’s need for cost containment. The 
challenge is occasionally that the rules regarding generics, they can be 
plus or minus 15% in terms of their potency so you can get medications 
that are more potent or less potent than the brand name and it can 
occasionally lead to problems for some patients. I would say the majority 
it’s certainly not a major problem but I have had more than a few patients 
who had difficulty either with tolerance or with lack of full efficacy 
probably related to that reality. 
- I: so in that case you would ask the patient to pay for the branded drug? 
- P: No, what I do is I would – they may try a different generic brand, or I 
write no generic substitution and to be honest with you when I write that, 



























recently is the name brand products are now starting to offer up 
themselves through different avenues, once their patents expire and they 
are genericized, some of them are still finding ways to allow ODB patients 
to get brand name products. They either drop the price or they make them 
available in another way. So I see that market growing as well. But ya, by 
and large if someone has a problem with tolerance, they will either try a 
different generic or will try and see if they can get no generic substitution 
approved based on their specific complaint or reaction. 
- (what is your take on generic drugs in terms of their effectiveness?) well 
scientifically, scientific studies have shown while they may vary in the 
term of their active component of ingredient, that has to be tested to be the 
same. I do have some patients – who do notice some differences for 
certain medications, but it is unusual for patients to say they want the 
original brand because it is not as effective or giving them side effects. 
Although with the change in oxy-contin to oxy-neo, I have had patients 
who have complained, but that’s understandable, that is a different issue 
(laughing).  
- The other problem is the generacized brand you have to use – for example 
there is a medication, three or four years ago, was generacized and is no 
longer branded, it is a high blood pressure medication, it is supposed to be 
an extended release medication to last the full day, and the genericized one 
is supposed to perform the same way, but they found that the generacized 
one actually did not protect the patient the same way as the brand name 
medication, but once the genericized name is on the market, the brand 
name medication was no longer part of the ODB, so you have a number of 
patients coming back with the genericized brand but the blood pressure no 
longer controlled. In that case, the drug company supplied the doctors 
with a card to tell the pharmacy to substitute the generic with the branded, 
but if I ran out of cards, then what do I do? Certain stomach medication, 
the ones for the acid, they don’t work the same so the brand name works 
way better compared to the genericized, I would have patients who were 
on the brand name medication, when it came genericized, went to the 
generic, and they would come back and say this doesn’t work, it used to 
work all the time, it doesn’t work anymore. Same with certain birth 
control medication, they substitute it with this generic brand, and the 
generic brand gives the side effects of more breakthrough bleeding, so 
instead of keeping your cycle regular, the genericized brand, would cause, 
mid-way through, you would bleed, so we have to switch to a different 
brand that is not genericized or a different brand that works for the patient.  
- (when asked about opinions on genericized drugs): there are certain 
specific instances where you have a generic drug that wouldn’t be 
preferable. If you are giving antibiotics to kids, the generic always taste 
lousy and you will have a tough time getting into a picky kid. But that is a 
small point. But in terms of all the other medications, the generic and 
brand name thing are identical. And when people come in and say I can’t 



























about it, because at that level, chemistry is chemistry, there is not  whole 
lot of difference. Now if they swear up and down I’ll take them off it, I’ll 
buy into it because I’m not in your body, but I have my skepticism, I 
certainly think generic drugs – and as I said, the generic list on the ODB, 
you can practice a ton of medicine and do very well with it. What is 
covered will do a lot of work for ya.  
- I have had a handful of individuals that would say the genericized version 
didn’t work for them and they can tell that in a backwards way. I would 
prescribe them the branded drug first when they are 64 and when they turn 
65 and they go on ODB coverage and get genericized version and they say 
I can’t take generic one I need the branded one. And I don’t know if it is 
simply human beings giving brand loyalty, and deciding that they want 
that or whether or not they think the more expensive drug is the better 
drug, I’m not sure, but that would certainly be worth investigating as well. 
But again I tell them, I’m not going to argue with you if you think it is 
worse, but I think if you stay with it for a while you might find that it 
doesn’t make any difference at all. Sometimes I win that argument and 
sometimes I don’t. sometimes they come back three weeks later and say it 
is still a piece of crap and sometimes they say it works. So it is one of 
those things that you can’t predict ahead of time. I mean if you give a 
person a generic drug and they have a full anaphylactic reaction I’m going 
to wonder how could they have been on it in the first place, right? Because 
they should have gotten sick while on it when it was a brand name, so that 
makes me skeptical that it wouldn’t have been the drug whatsoever and it 
was probably something else that got them in the soup so then you have to 
practice medicine and do a bit of thinking as to how they got the way they 
were. 
- I didn’t do the research so I can’t argue, but certainly from my experience 
with patients coming back, you see the difference. And the one with the 
blood pressure, there are numbers that show you it doesn’t work the same! 
And you can’t argue with that either. I mean they can say that, but I don’t 
know, I would say not all medications are created equal. There are certain 
ones that I don’t have problems with but there are a few of them that have 
those kinds of issues. I don’t think you can 100% say across the board that 
there are no problems, I think that would be wrong. They are not 
problems; they just don’t work the same. The one with the high blood 
pressure one, it is supposed to last 24 hours, but they noticed it would 
work for the first 6 hours and it would lose its effectiveness by the evening 
so you would get fluctuations with the blood pressure as the day goes on, 
that doesn’t work! For blood pressure medication to work, you don’t want 
to have that amount of fluctuations on a daily basis, that is when you want 
to protect your heart and arteries and all that stuff, so I wouldn’t say it is 
the same. I was talking to my colleague about this; and they were saying 
about warfarin; Dupont did a study that compares the generic brand and 
the name brand, and the conclusion is that – with warfarin, as you know, 





















INR levels, which is how thin your blood is, and if you switch from one 
brand to the next, it will change you INR and it can sometimes increase 
your risk for stroke and bleeding. So, what happens when this patient goes 
to the pharmacist and one day they get this brand, and the next month they 
got the next brand, is the patient notified? And the answer is; We don’t 
know! So the onus is on the patient to say ok, look at the bottle and see if 
it is the same brand on a regular basis. If it is the same brand, then you are 
ok, but If it is not, then you might have a fluctuation in your INR that is 
not explainable. So my colleague tries to tell his patients if there is a 
different brand, then you will have to come in to do your INR test earlier, 
just so we can see if there is a fluctuation but then I’m thinking, you are 
using more money in terms of the healthcare system! And that potentially, 
with warfarin, can be a huge issue, and for the elderly, most of them have 
no idea – oh I’m taking that yellow or pink pill, they don’t necessarily 
look at if it is generic, or a different brand. It is hard enough for them to 
just take that medication you know? So that makes things a little more 
complicated. I don’t know whether the pharmacists alert people to those 
kind of issues or not.” 
- The pharmacy would probably come into play, like I would say, I don’t 
know if there could be a policy in place to say to the pharmacists once a 
patient starts on this medication, they need to stick with it and don’t 
change it, and if there is absolutely no way of doing it, then change it, but 
you need to notify the doctor, that might be a more safe way of doing 
it…but would be up to the policymaker or we mention to them that this is 
a problem, and can we have a policy that says you use the same brand but 
then there will be times that certain brands may not be available so you are 
forced to change brands because it is better for you to continue with some 
kind of medication than nothing at all.  
- There are certain drugs that are covered (In ODB) that are still brand 
name, until they become generic. 
- I have no problems with generic drugs because scientifically they should 
provide the same effects, I mean there are strict guidelines. Having said 
that, I can’t be sure if every drug company, and every generic drug 
companies, I assume there is some government oversight, so I can’t really 
compare different generic drug companies and generic brands, I just can’t 
make that distinction. Certainly if I notice any change in effect of a 
generic compared to a brand name, then I will quite readily complete a 
form to get them access to the original form. Whether it is a patient 
request or I see it necessary. 
- I have touched on some of it already. I think if they were much stricter 
with the generic competitors with the tolerances in terms of the potency of 
medication so instead of plus or minus 15% make it plus or minus 5%. 
Make the generics much closer to what the brand names are in terms of 
potency, that would reduce the number of people who have complaints as 
they are making the transition. 
- I’m picky for generic versus brand because it is all about affordability. Do 
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I think the brand names do a better job? Yes.  But they are very expensive, 
we have to deal with the cost. So the generic to me is not a big deal, it is to 
get the job done. I have had to switch people from brand to generic and I 
think they had a problem or their blood pressure increased a bit so I know 
there is a difference, it is not life threatening unless you are allergic to 
whatever they use in the generic, I have seen people like that. So to me, it 
is not a big deal. 
- I: so even the increase in blood pressure is not a big deal? 
- P: no, you can always increase the dose or add a little bit more medication 
– if there is anybody to fix that issue, it is the pharmaceutical companies – 
they should decrease their prices. To me it’s usually not a big change, 
even if there is increase in blood pressure, it is not too much, it is not life 
threatening.  
- I think the issue that has come up with the oxycontin issue, so oxycontin 
going to oxyneo, I think the government was aware that there were 
problems with oxycontin for years before it was discontinued abruptly this 
spring. First of all, we had no warning that oxycontin was going to be 
discontinued but the government said that they were stopping it because of 
its addictive potential and it was a dangerous drug, well if it was so 
dangerous, again, they could have stopped it sooner, but also they didn’t 
put any increased addiction services and chronic pain services in place for 
those who needed to do the transition. Another issue is with the duragesic 
patch, I don’t know if you are aware of that, so duragesic is the brand 
name for the fentanyl patch and the government stopped paying for that a 
few years ago but the patch they covered is apparently more easily abused 
by people who want to abuse it. So the government says they are 
concerned about drug abuse and addiction yet the only patch they cover is 
the one that is most easily abused. Whereas the brand name might be a bit 
more expensive, but again, the information I have been told, is that it is 
harder to abuse the duragesic brand patch, so again I think the government 
is giving mixed messages. They say they are concerned about addiction 
but they don’t provide resources, you know. They are paying for 
essentially the cheapest brand but that might not necessarily be the best 
way to go.  
- I: when you mentioned problems with oxycontin for several years, did you 
meant problems with addiction 
- P: yes, so addiction, misuse, now being sold on the street, prescriptions 
being diverted – patients would get a large prescription and sell it on the 
street. 
- I: so oxyneo is its equivalent? 
- P: yes, so it is a different – the tablet can’t be – if you try to crush it or 
melt it or snort it, it turns into a snot like gel, so it is apparently harder to 
abuse, although there are ways to do it apparently. 
- I: I was told that it doesn’t work as well either, I have heard that there are 
a lot of patients complaining in comparison to the branded version. 
- P: yes that is right, it is not as effective. 
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- I: so have you seen that over other medications when comparing branded 
to generic? 
- P: you get anecdotal, I have individual patients that say that when the 
company – well I had a patient yesterday who’s pharmacy has switched 
from one generic brand of warfarin which is a blood thinner to another 
brand, and then her blood work was actually different, and she asked me if 
that could affect it, but then in the end I found out she was taking 
Naproxen which is an anti-inflammatory that will definitely affect that. 
But ya, I have seen differences between when one generic is substituted 
for another, or when the brand name goes off the list, and then they are 
switched to a generic, changes with say thyroid –  
- I: Is the switch concerning to you? 
- P: it can be upsetting to the patient, but there are always ways to work 
around it, so in the big picture maybe it doesn’t make a big difference if 
you are having a different clinical effect. 
- I: I know I have also heard that sometimes physicians do not know 
patients are given the generic from the branded at the pharmacy? What is 
your opinion? 
- P: ya that is an issue, I guess in my point – I have to have some trust that 
the scientists that are looking at these drugs within the ODB program, that 
are providing – or the scientists that are providing advice to the program 
have the qualifications to say it – you know be confident that the generic 
brand is close enough to the brand name. And I guess you are also trusting 
that the generic drug manufacturer has quality controls in place and that 
every drug they produce is standardizes and there is good quality control. 
So there is a lot of ways along the chain where the patient might end up 
getting a slightly different dose or slightly different effect than the 
branded. I also think that sometimes the brand name pharmaceutical 
companies make this a bigger issue than it is for marketing. I mean as 
physicians we are exposed to a lot of direct marketing by the brand name 
pharmaceutical companies so there are a lot of incentives to prescribe 
brand name, so again, I think at times the benefits of the brand name drugs 
are overstated compared to the generic. 
- I find patients complaining about side effects of generic of generic drugs 
and they say it doesn’t work as well as branded so I have to switch my 
patients sometimes from generic to branded 
- Maybe ODB should add one branded medication per group of medications 
to the formulary for those patients who cannot handle generic drugs due to 
side effects. 
- I see it as individual based in terms of effectiveness between generic and 
branded drugs. 
- lots of patients complain and want branded drugs 
- in general, not a lot of differences between generic and branded so I don’t 
know if it is the patient’s impression because they are told to switch to a 
cheaper drug, or they actually react to the slight difference in ingredients 
between branded and generic. It is obvious they are complaining though. 
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- I can understand their reasons for all the groups that they have umbrella’d 
under this program, there are certain aspects I don’t understand, is the way 
they pay pharmacists- I think up until a few years ago, generic drugs were 
calculated at 50% of the branded products, so that’s what they were 
paying pharmacists (the government) for those drugs and generic drug 
prices are still considerably higher here than in the U.S. and I think 
recently they changed that to 25%, so they pay pharmacists 25% for that 
generic brands, which is still considered too high, and it prevents 
competition, it prevents consumers from getting the cheapest prices. I 
think a better method is to pass the cost on to the consumer and let the 
government reimburse the consumer for the drug that they get and that 
should create that competition  - no incentive for pharmacists to lower 
their prices if they are getting a flat fee for each generic product that is 
dispensed. It just allows generic drug companies to try and provide 





















- I think a faster track for newer medications, if these drugs are proven to 
work and they are often proven to work before they come out, before they 
are available for use by us, maybe a quicker way of streamlining the 
process to get newer drugs on the program. As I said, maybe a different 
way of the government reimbursing – I mean paying for these drugs, 
rather than just flatly paying 25% to pharmacies. I don’t know if that may 
reduce the cost of medications for all people who don’t fall under the 
program, maybe be a little more inclusive – I haven’t looked at the trillium 
program to know how it excludes say a middle class family who has a 
sizeable part of their income devoted to healthcare, whether they would 
probably benefit from being included in it. Other than that, I think get rid 
of the LU codes, get rid of the EAP, just have the drugs on the formulary, 
have them available without stipulations. Just trust doctors to make the 
right decisions. 
- The single most important thing about it is that people won’t go without 
care and therapies. How could you take a mom who is on welfare and has 
a kid who has a strep infection and decide not to give her the medication 
for it because she is deciding whether to get formula or the antibiotic and 
she can’t afford either. The whole thing about the country we live in, is we 
are pretty decent at looking after those individuals at the poverty line, we 
are not perfect but we certainly try and we try harder than the boys down 
south. The most important thing undoubtedly is people get the therapy 
they need and I don’t think it is sub-standard. As I said, you can practice a 
lot of medicine on the ODB program and do very well. If that was the only 
book you had to pull drugs out of, you would be the popular physician in 
town believe me. 















































thing would be is the lag between what we think is a drug that should be 
covered and what they are going to cover. And there can be situations 
where they grind their heels in the ground and say we are not going to put 
this on the list and that is important when you come up with good 
innovative new therapies that are expensive because the drug companies 
are trying to recruit the R and D on it so if you want to put people on 
fentanyl patches which is an excellent method of giving people chronic 
pain relief without popping pills all day long, that is an expensive delivery 
mechanism and that is going to be born by the program and at some point 
if you are the program director, you will say wait a minute we do the 
checks and balances on what this is going to cost us and some things we 
can afford and some things we can’t and I respect that that is why I’m glad 
I’m not the person making those decisions. But I think when enough 
pressure comes to bear and enough people make a noise that they are 
filling in all kinds of EAP forms for a particular therapy, I think that they 
are going to wake up and smell the coffee and say ok we better re visit that 
drug and put it on the ODB formulary. I’d like to think that is how it 
happens, of course another thing is they may just say that there is no way 
we are paying for this. I don’t know. So your question about the design of 
the system is such that: The people that I know that can’t pay for drugs, 
get drugs because of the ODB – that part of the design is perfect.  
- I don’t think so, I think that is it. You know, I would like to see them 
promote among the brand name drug companies a strategy that once the 
patent has run out, that they routinely drop their prices so it gives us the 
option of sticking to the brand name if we choose. 
- P: well I think I’ve seen more efforts, you know one example would be 
the proton pump inhibitors, you know the PPI drugs that are used for acid 
suppression, they require a LU code now, but I have seen information 
saying you know it is reasonable to start with something like zantac which 
is in a different class of stomach drugs, which is much less expensive 
because again we get pushed to prescribe the more expensive PPI’s so a 
lot of those are prescribed when something less expensive would probably 
do the job for 80% of the people. So I think there has been 
communications like that, I think there is some minimal effort to 
encourage us to think about what are you prescribing, is there something 
less expensive, is there an alternative, same as antibiotics. 
 
- The problem is that, our whole healthcare system has a problem – we just 
don’t have enough money to fund everything. And to continually have 
new medication that are expensive all the time, that can suck up a lot of 
money, so you do need kind of checks and balances to limit the amount 
that you use, so you can still benefit everyone. In utopia, you would have 
money that falls from the sky, and you can supply everything, but in real 
life, it just doesn’t happen.  
- So I think Canadians in general are very spoiled to a point where you can’t 














government to pay for everything and to be able to have access – 
personally, I feel, to be able to have access to what we already have, is a 
huge benefit already, of course there are always going to be ways to 
improve it, but you also have to think of, in some ways, the big picture, 
can we afford it? Is this something we can afford? I feel that the 
government is already using some ways like using the LU codes, so that 
physicians don’t abuse it in such a way that you don’t always use the most 
expensive drug, in lots of cases you can choose the less expensive drug 
and still do the job well, but because of marketing from drug companies, 
we have been bombarded by that and influenced by that somehow right? 
So you might choose the more expensive rather than the ones that are 
potentially cheaper. I do feel that ya, there has to be some kind of 
limitation, otherwise, we can’t afford it, it is a good way to have some 
checks and balances, and I think they are doing their best, but I sometimes 
wish there are ways to communicate that this is a more urgent approval, 
look at this first – especially for section 8 requests. The process of getting 
that to happen takes physicians to advocate for their patients more. 
Luckily there are people who advocate for their patients more and so it 
works well that way. 
More 
Transparency 
- I would like to see more transparency in how they make decisions, right 
now it is really a black box… 
- I would like to know the reasons why we have to complete these codes 
and these forms. If they are just a pure financial reason, then they should 
be upfront about it. I don’t think we try to waste money, and we certainly 
don’t want to prescribe more expensive drugs if the cheaper ones are just 
as effective but sometimes trials may not tell you exactly what patients 
need. Patients are more informed these days and are requesting newer 
products and they even have access to studies and are able to research 
studies, especially is these drugs have been approved south of the border, I 
don’t want to not be able to prescribe these medications. 
- No, I’d like to know who makes the decisions when we complete these 
forms, who actually determines the patients’ needs based on a piece of 
paper, and how objective that can be and how they are able to determine 
the patients’ needs better than their own physicians either me or a 
specialist. I imagine they sometimes feel physicians cower to demands of 
their patients and without specific scientific reason, or objective reason to 
do it – and that sounds reasonable to me.  
- They take off drugs at various times on the list it’s hard to keep up with 
what they cover and what they don’t 
- No I think I covered everything. It’s quite foreign to me, I mean I have 
only been here for six years, and being in a country that you have a 
program like this, it is a great societal justice to have something like this, 
not everyone has this. Even a country like the U.S. they don’t have as 
good as a system. It is great to have the program, but is there room for 
improvement? Absolutely. It is going to a little bit of investment, special 
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training, and timely review, update it frequently. 
- Do you know if it has been updated since 2005? 
- I: personally throughout my thesis writing experience, I have had an 
incredible amount of difficulty finding information. 
- P: because it is not published, it doesn’t look like it. I can still use – all the 
drugs I use today are the same ones I used in 2005, I haven’t seen a lot 
added or changed. 
- I: I have seen a lot of documents on the MOH website but specific 
literature reviews or studies, I could not find. 
- P: there is a lack of that, do you agree with me? Lack of evidence base and 
lack of timely review. 
- I: yes, it is either a lack of it, or it is done and nobody knows. 
- P: exactly, if they do do it, we don’t get any notice of it, you know, you 
are not aware of it. I mean why keep it quiet? 
- I: do you feel LU codes and section 8 forms limit your prescribing 
abilities as a physician, earlier you said yes, but what about with the LU 
codes, you mentioned section 8 limits, but what about LU codes? 
- P: well LU also limits, due to the criteria you need to use. I think you 
know, the step up approach – that’s why I say evidenced base and the 
formulary doesn’t keep – there is a bit of a disconnect between them. If 
you look at asthma, asthma treatment as a step up, it doesn’t feel that it is 
as easy to prescribe the medication for asthma prevention in a patient that 
fails his initial treatment. I might be wrong but it feels to me – and even if 
you have a patient with COPD or an exacerbation, a prescription with a 
cortisone, it is very difficult to argue from the criteria we have at the 
moment. So definitely some conditions where you would use medications 
with a clear conscious and evidence base behind it, as the appropriate drug 
and my feeling again is the formulary is not timely reviewed, it doesn’t 
keep a base with newer guidelines, newer guidelines for hypertension, 
newer guidelines for asthma, newer guidelines for diabetes, again, the 
more vulnerable population is deprived of the most recent drug treatments. 
- So they should keep up with guidelines, because guidelines are reviewed, 
if you look at hypertension, it is reviewed, possibly every 5 years, some 
medications are changed, medications are taken out, well if they can do it 
on a timely basis every 5 years, they could keep up with all these other 
guidelines. And I mean I understand the cost containment is a major, 
major factor, but, it could become so cumbersome – this is the whole idea 
behind evidence based medicine, if you do treat, you treat your target, you 
want to achieve something with the medication, you want to do something 
with the medication and if you have to treat patients with a medication 
that is not as effective anymore and there is more efficacious medication 
available, you are going to end load that whole process because you are 
not going to achieve your target, you are going to have the complications 
down the road,  so you may save money right now but 20 years down the 
line maybe not.  
- So it is wise for them to invest time and effort in reviewing it and keeping 
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up with the guidelines, and still go for the generic cheaper drugs, and still 
have guidelines in place, you know, I have no problem with it, because as 
physicians we can be wasteful, you know, I can’t speak for everyone, but 
we can be wasteful, so I don’t mind the guidelines, its two sides to the 
coin, they have to keep to their part of the bargain as well – keep it timely 
and keep to the guidelines.  
- Lack of evidence based, and lack of timely review. We do not get any 
notice of reviews, doctors are not aware of it.  
- Be very transparent of the criteria for how medications get approved. So 
that the medical community - I mean they probably are and I don’t spend 
enough time to research it but just ensure that we have medications 
available to us that are widely recognized by evidence to be effective. 
- P: you know they do send updates all the time on what medications have 
been added to the formulary, what medications have been removed, it 
might be worthwhile to put a little sheet that serves as a basic reminder of 
what basic policy is with the ODB, in other words, how do they select 
medications to stay, how do they select medications to be removed, why 
the policy, why the necessity of a LU code and a section 8 strategy. Like I 
said when we get these regular handouts telling us what’s changed it 
might be a useful piece of information upfront.  
- Umm, no, just that if they can find a way to update me with the new 
medications and the ones they have taken out of the program, that would 
be beautiful. Because you write a prescription and you think I know this is 
covered by ODB and they tell you it is not, I’m thinking but I thought I  
wrote this two years ago for someone, so if they find a way to – if its 
sending something saying this is no more covered or this is covered, so 
you know. That would be perfect for me.  
- No, just inform me. 
- I want to believe they have members of the public, pharmacists, few 
physicians when they make their decisions because – and the reason I say 
members of the public is because as a physician, I want every medication 
to be on ODB but that is not realistic, if everybody is on the boat, then 
everybody can make a decision on which one should be and which one 
shouldn’t be. But if every medication is there that would be beautiful so I 
don’t need to think about it when I write the prescription. I think it is a 
very good program. I have practiced a bit in the UK and they kind of have 
something like this but not as good. I didn’t think it was this good and the 
UK is the best out of Europe. I noticed that most of the medications, you 
had to go through a lot of hoops like the LU code is not monitored here, 
you pu LU code for everybody, but in the UK, most of them you have to 
go through different hoops before they approve it. And I think what’s the 
big deal, if it is million dollar medication maybe, but here you just put the 
LU code and pharmacy gives the medication. So it is easy, I am not trying 
to say that they are loose, but they are easy and easy for physician as well 
as patient and pharmacists. I just don’t like the section 8 – like the patient 
I told you about – maybe they have certain cases that they have to approve 
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within 24 hours, but it took quite a while and they came back and said no. 
I’m sure they have a budget, but I don’t like section8.    
- The website I find it’s not the easiest website to navigate, although I think 
there have been some improvements made. Actually I think the website is 
better than the paper binders that - they used to mail out paper binders like 
these huge things of paper that we had to then put in to different sections 
in a binder and it would come with every update because it was with the 
new LU codes and the new section 8’s but they have stopped that which is 
a good thing, because it was a waste of paper and a lot of the doctors – 
that would just go into the blue box or the garbage. I think just enhancing 
accessibility of their website. Probably doing more active education or 
doing more education about evidence based medicine but – I mean one 
example of that – I don’t know if you have seen the orange book at the 
clinic called The Guide to Antibiotic Prescribing – this is actually an 
evidence based prescribing for antibiotics, it is Ontario based, and they go 
through sort of the choice of antibiotics you should use, the cost per day as 
per the ODB, but that is the information doctors need so it is handy and 
because of that initiative, I have seen prescribing patterns changing I think 
if you just have ongoing education with physicians about appropriate 
prescribing practices we could probably save the ODB program some 
money. I guess the trillium program – a lot of patients – people don’t seem 
to be aware of it and there seems to be a lot off paper work, there seems to 
be a lot of hoops to jump through to apply for it, people have to reveal 
their income tax returns and then they are paying upfront so it just seems 
to be a clunky cumbersome program that isn’t well promoted and not 
much known. And even then, if people do qualify, I have had some 
patients that have to pay their first $800 upfront, or their first $1000 or 
$1500 in medications upfront and that is often a barrier to them so I don’t 
know if there is a better way that that could be spread out over the year.     
- I guess another interesting thing – getting back to painkiller so chronic 
pain – the oxycontin issue is that people that actually qualify for the ODB 
program usually are the ones that don’t have any access to physiotherapy 
or massage therapy or can’t afford a gym membership or have so much 
going on in their life so there are other ways to manage their pain that 
aren’t available to them because of financial reasons so as physicians we 
are almost forced to prescribe them narcotic medications so they can keep 
functioning so it would be great if there was access to physiotherapy or 
other pain management resources.  
- The limited availability of physiotherapy directly ties in to the amount and 
type of drugs that we have to prescribe to people. And other things like 
you know cardiac rehab programs, we can go even farther that the people 
on welfare – you have probably heard of the welfare diet? You know high 
in carbohydrates, because they can’t afford fresh fruits and vegetables and 
then you have issues with obesity, high blood pressure diabetes, that I 
think it would be better to deal with those issues and do the preventative 




- I: so this ties into primary prevention and basically the healthcare system 
in Canada is trying to turn towards as opposed to the traditional secondary 
or tertiary prevention means 
- P: Right, right now we are paying huge amounts of drugs, but you have to 
ask can this money be spent elsewhere and I think the government has got 
that and I think they have started focusing on that. The focus on diabetes 
is certainly out there and the focus on – I don’t know if you know last 
week the OMA put out a paper on childhood obesity. 
- I: so you are saying expanding the ODB to not only drugs? 
- P: Ya or, just saying look, we have this limited amount of money to spend, 
why are we spending it all on drugs? But at the same time I would hate if I 
had a patient with diabetes that came in and needed the medication and the 
ODB would say that we don’t cover diabetes medication anymore because 
that is a lifestyle, that is the patient’s fault, so they would have to pay for 
it, you also don’t want that type of society. If people need drugs, they 
should have access to them. 
- As a physician, I will be happy to be more informed about policies of 
ODB either by sending me quarterly info on changes for example. 
- I would also be happy to get information on any new drug – that is a LU 
drug. For example, we are usually informed through pharmaceutical 
companies and not ODB themselves – I would rather hear from ODB. 
Need more communication between ODB and physicians 
- I’m happy making patients happy by knowing more information and being 
more educated 
- I think ODB and physicians should communicate more. 
- I would like to see ODB cover as much as they can and I want to see more 
drugs covered for my patients since they are my primary goal and making 
them healthy 
- Everything we do is for the patient we are here for them so by me 
collecting more correct information, I can better deliver care to patients. 
- In general I am very thankful for ODB covering meds especially when 




- I know in some provinces, when you start a new prescription, or you give 
a new prescription to a patient, that they say that the provincial program 
will only pay for a 14 day supply initially in case the patient has an allergy 
or an adverse reaction or can’t tolerate the medication and I actually think 
that is not a bad idea because right now, we can write like a full three 
month prescription and then the patient will come in a week later and say I 
can’t take this medication and so then all of a sudden you have 90 pills 
that have been wasted. So that is one thing – having for any new initial 
prescription for chronic – I’m thinking about chronic diabetic pills, blood 
pressure pills, heart pills, anything like that, maybe a limited quantity for 
the first prescription would be a good idea.  




- I wish the ODB would consider covering for more medications and 
provide less limitations specifically for medications most often used or 
prescribed. 
- Ex: Ciprofloxacin 500mg is for the elderly but only under LU code and 
most of those patients have chronic UTI’s and require Ciprofloxacin but if 
they do not qualify, then they have to pay for it.  
- 1. The MOHLTC should talk to primary care providers and see their 
concerns with prescribing meds 
- 2. Designing simpler forms to fill out to save physician time and at the 
same time still providing all the important information to receive approval 
for coverage 
- 3. Involve pharmacists’ views in ODB development/improvement of ODB 




- (when asked about primary prevention and how primary prevention is 
halted if the diabetic medication is not covered) It is a bit too late to try to 
prevent something that has turned into an epidemic. Possibly – although I 
don’t think for patients it is the lack of equipment that prevented them 
from checking their blood sugars, I wish it was that simple, but it is a little 
more complicated looking after patients’ health, it is more than providing 
them access to healthcare, or medications or even to equipment, 
screenings, or checking, it’s trying to change their – not so much their 
attitudes it is their behaviour which falls outside the program. 
- The trouble with primary prevention is the benefits have to far outweigh 
the risks, that’s the problem. Because people who are in primary 
prevention, don’t have any symptoms and so don’t feel anything bad. So 
when you are giving them an intervention, it must have a dramatic benefit 
compared to the risks and so if it has any side effects, they won’t take 
them and that’s the trouble and with those kinds of medications, it is not 
easy to get the data for, to say it has that kind of benefit and it becomes 
expensive to get that data and in turn the medication becomes expensive.  
They will look at things that cost as little as can be in order to get the most 
benefit and the drugs that do that are the secondary medications and 
tertiary medications are the medications that are the ones that sadly, ODB 
will cover, and the primary prevention ones won’t be. By not treating 
certain primary prevention things, absolutely, you will have patients who 
progress on to having the disease – so for example, one of the things that 
we have been dealing with most recently is the shingles vaccine which is 
not covered by ODB at this point, it is not a perfect vaccine, it covers and 
reduces the risk of shingles by about 50% percent, it reduces that risk for 
the post shingles pain which is a terrible debilitating pain that patients can 
get by about 50%, so it is not perfect but it’s the only thing we have that 
prevents. There are medications that you can give once the patient has 
shingles in order to treat the shingles and prevent the actual onset of this 
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post shingles pain, and there has never been a study that tells you how 
much it reduces the risk of post shingles pain, but the government is not 
paying for prevention, but they are paying for the treatment of the shingles 
and the pain control that is required when you get the post shingles pain. 
So that is a very black and white thing we see now, that if the government 
does pay for the shingles vaccine, it needs, I think, about 1000 patients or 
350 patients or something like that to prevent post shingles pain, so the 
numbers are high, but that case, if you are the one out of that number, you 
want to have that shingles vaccine, you know what I mean? 
- As policy makers they need to balance the value which is the benefit of 
that particular intervention with the cost – which is not just the side 
effects, but actually monetary cost and right now it is a black box, I don’t 




































- There are certain medications where you need to get a specific permission 
under the EAP which takes up time, and sometimes makes you think twice 
about prescribing those medications to patients – which is not necessarily 
a good thing. I don’t see the point for us requesting special access for 
medications we think are best for our patients. 
- “I would wish that the section 8 – there would be some form of reminder 
or a letter sent to the patient saying that it will run out, and if you require 
further medication, please contact your doctor because it should be the 
patients’ onus to tell the doctor to renew it. 
- “In terms of my experience and interaction with the actual government 
agency, I don’t have a face to the government agency, they are usually 
forms that I fill out, that get faxed and I get back, and responses from 
certain adjudicators based on the information I submitted, I remember for 
a while, the EAP or section 8 process took a long time often times it takes 
months before the return of a notice whether it is supported or rejected, so 
I guess with those things, it has given me less interest in pursuing those 
kinds of submissions and it has made it more and more painful to try and 
make a submissions, so, to be very honest, the things that I do, often 
times, try to circumnavigate having to go through those kinds of 
processes.” 
- The EAP form takes a few weeks before it comes back. I imagine you also 
– I mean, with the program, you have to have some framework for 
providing medications, with a set budget, and I imagine if brand names are 
so much more expensive than generic medications, 25% compared to 
100%, then they have to make some kind of rule, and it is reasonable for 
them to expect us to provide further information, which is often 
embellished.    
- They need to remove section 8. 
- I don’t think they should be de-listing drugs patients need unless they 

















































should allow doctors to use discretion in prescribing meds. We are 
cautious when it comes to cost and if they don’t think so, then they can 
education us about cost effectiveness. 
- Remove section 8 
- Not de-listing drugs unless deemed unsafe or not efficacious 
- Removing deductible each year 
- (when asked about Section 8 forms): I don’t think after I have done it 
properly and dotted the I’s and crossed the T’s, I have ever had one 
refused. They are very, very good about that. If you do the paperwork, 
they are probably going to give it to you. And for that reason, I think that 
if you think there is an Exceptional Use – I think, philosophically they 
don’t want to deny a person to have the chance to have the drug that is 
best for them and they are letting me and the patient decide what that best 
is. They are not getting involved in the therapeutic contract between me 
and the patient, but they are going to give me guidelines about what we 
should probably try first before we end up breaking the bank and again 
that’s their mandate and I don’t have a problem with it.  
- Many many, many things are covered by the ODB, you can certainly 
practice a lot of medicine just on a list of drugs on the ODB, you don’t 
have to be an outlier, you can be a doctor that says I ‘m not giving 
anything that is off the ODB and you would still have lots of patients. So 
its those exceptional cases- I don’t think I do very many EAP forms do I 
do a year – I doubt 6. The LU codes I certainly do a few a month 
obviously.                        
- I am ok with section 8 forms if I know ahead of time to fill it – it takes 
time for approval and that is not good for patient sometimes if they need 
meds immediately. 
- I usually like to tell patients to be on time with the request in order to not 
run out of medication because it takes time for approval. 
- I don’t have experience with section 8 request being rejected – I am lucky 
so far. 
 
- YES! Definitely, it is quite a pain, because I don’t remember all the codes 
– it is quite a pain to look through them every time you want to use it. I 
mean, by now, we know most of the criteria, but some of the way that you 
are asked to use it, may not necessarily be most beneficial to the patient so 
certain drug of choice that I would put on, with a certain condition, I 
couldn’t do it because the LU code doesn’t allow for that condition to be 
used, especially for antibiotics, well then you can’t use it. You either have 
to ask patient to pay for it, which most patients will not, and they would 
basically ask you well prescribe something else then. With the section 8, 
again, it takes an approval process, the approval process takes time, and 
it’s not in a matter of a day you get approved, it’s usually weeks, so my 
experience is that one patient that required a certain type of pain 
medication that is in section 8 only, she was in quite a bit of discomfort 















































medication was one of the ones that have been tried and it worked but we 
couldn’t prescribe it until we had section 8 approval and we waited 8 
weeks and that is a long time, so she was in pain while waiting for it, so it 
is a little bit difficult in that regard. But the other thing, is that it relies on 
– the onus is on the physician and patient to remember to renew the 
section 8 forms. Which means, 8 weeks in advance, at least I trie to do 
that, I give myself a reminder so that I would write a letter on behalf 
saying this needs to be renewed and you need to give an update on the 
patient’s behalf, write an update on their health, why you continue to need 
it and what medication has been tried and you need to do that every year. 
Unless you remember, you won’t know. Some of the pharmacies are good 
in saying it is running out but the majority of them they don’t tell you so it 
is up to us to remember to renew it, otherwise there will be a gap. There 
are certainly, I remember, there weren’t any rejections (from section 8 
requests) they didn’t really outright reject it, I think the reason this patient 
took so long, (the above patient), as far as I can remember correctly, I 
think was happened, was there was a letter sent back to me asking me for 
more information before they approve it, but so far, I don’t think I ever 
had an experience where it was rejected, maybe once but I can’t remember 
exactly.  
- My wish list is that there is easier ways of not having to go through the 
book for the limited use codes, because every time we do that, we spend 
more time with the patient so with all the letters we have to write and 
different things like that…” 
- Yes and no, yes in that my opinion is not as big as some who may have a 
majority of third party payers within their practice, or patients who have 
third party payers, so often times I will look at any class, or any particular 
indications that are required that have a list of classes of drugs to treat that 
indication and because ODB only covers certain things, I will limit myself 
to being very conversed and remember those particular drugs. A good 
example is a drug called Celebrex, which requires an LU code in order for 
you to use it, for good reasons, an requires three particular different anti 
inflammatories before actual use for it to be covered under LU code, so 
what happens is I make myself very familiar with three different types of 
anti inflammatories and pretty much, I don’t think about any other anti 
inflammatories, and if I need something else, I’ll go to Celebrex for 
example. In a sense, I have limited what is functional to me, I feel like I 
need to know certain things in order to jump through certain criteria with 
the ODB benefits and therefore I have limited myself to knowing those 
things. No in a sense that I am still open to using medications that are not 
part of the ODB, there is a number of different diseases that don’t have 
good treatment in ODB and so medications for IBS, or fibromyalgia, 
chronic fatigue syndrome, even though there is now new medications 
being listed under ODB, so certain treatments for those types of disease 
that ODB doesn’t have coverage already, I’m free to pick whatever I want 






























I would li mit my functional knowledge to what is covered by ODB, and 
then supplement that, so oftentimes I would end up saying ok these are the 
things that I treat regularly, I get very familiar with them and those things 
that I don’t are often ones that are not ODB covered.  
 
- I think what’s frustrating is that the ODB has different levels of benefit, 
which requires different levels of process in order to get the benefit and 
that is frustrating, I’d like to see – if something is covered by ODB, then 
cover it, don’t give me different hoops to jump through to get it covered 
based on whatever criteria that ODB uses.  I think – they have, from their 
point of view, treatments get more and more expensive as new things 
come out so in order to contain cost, newer treatments have to go through 
a process of these different – whether it be EAP process or LU process, 
before they getting general listing and to some level, that makes sense, but 
others, it doesn’t. and it is not a transparent process,  I don’t know what 
criteria they use to evaluate; ok so the cost of the drug is this,  and we will 
put it on the LU code because of efficacy, cost etc… -  I don’t know what 
criteria they use to decide upon that, one of the things I’d like to see given 
that they do regular testing particularly on the new agents that come 
through, is having a monthly or quarterly review of things that they have 
investigated – so they do studies all the time about the efficacy of certain 
drugs that have come out, it would be great if we can get as clinicians, 
what ODB has done in terms of the research and how they came to the 
decision; it doesn’t have to be so lengthy that we get bored of it, a 
synopsis of the decision making – a little bit more transparency about it. I 
guess the bad thing would be, they would get complaints because 
whatever they decide, people will complain, so if they are not transparent 
about it, they don’t have to answer to us, but if they are then they have to 
be accountable for what they did.  
- The LU code which I don’t honestly see the point of, I’m sure other 
physicians feel the same way, really doesn’t inhibit me from prescribing 
medications because you are always able to find an indication which may 
not necessarily be the total honest way of doing it but if you feel the 
patient needs it you will circumvent that to get the medication 
- No, I think the only thing that would limit me is the list of medications on 
the formulary. Sometimes I may forget to write the LU code and the 
pharmacist usually just asks for one and doesn’t query the code I put in, so 
that doesn’t limit me. 
- It is a weakness, I’m not sure of their motif for putting it in, it might be a 
prompt or reminder to physicians that it is only approved for certain 
conditions, but I’m sure most physicians do not follow that rule strictly 
- It is good to help people who have given service to the country and are 
now retired.  
- I do. I feel that you know, I don’t know how well it is evidence based and 
whether it is reviewed on a timely basis – that is my biggest concern. 












years, as far as I know, I could be wrong. 
- And that you know, some patients, especially our vulnerable elderly 
population do not always benefit from newer evidence based medicines so 
I do feel it limits us. 
- My experience is that if you used a section 8, I don’t know how much it is 
used, we know that medicine is not a “cookie cutter” it is individual based, 
and despite formulating a great argument for use of a medicine for a 
specific patient, I have never had an experience where they have actually 
okayed it and said I could use it. My experience with section 8 is terrible. 
They have an approach that is very rigid and with little discernment and 
very little discretion, I think they have strict guidelines that they keep by 
them and I don’t know if the detail you always provide them with is 
valued. That is my experience with section 8. 
- Limited Use (LU), my experience with LU where I can name the negative 
is for instance the older population using medications for insomnia 
because sleep is an important function you need to sleep, it is as important 
as eating. At times you have to prescribe sleep medication, we know some 
meds are less addictive as others and we don’t have the privilege of using 
them and they have been generic for several years now; that is one 
concern. 
- Another example is a patient that had a recent angio – had stenting done, 
and because the Plavix didn’t fulfill the specific code, they didn’t 
prescribe it to the patient, and fortunately it did not block up his stent 
again, that would have been disastrous for him. So it does put patients at 
risk at times. 
- (when asked about perspectives on genericized drugs) Imovane is now 
Zopiclone, and we all prescribe Zopiclone as a treatment for insomnia 
because we all understand from the evidence available that it is less 
addictive than the diazepam, but we don’t have the privilege of using them 
because they are not on the formulary, they have to use Tomazepam and 
there is a greater risk of getting addicted to the sleep medication. While 
Imovane which is not generic – Zopiclone, should be quite cheap and it is 
still not on the formulary. So my concern is how do they review all their 
codes, and how often do they review the medications, do they keep up to 
date, is everything evidence based.   
- Whether they are as effective as the original? I don’t know if there are any 
big trials done that indicate the generic are not as effective as the original. 
I think in a country like Canada, I’m sure the standards are safe, and 
where it is produced, and they have to keep to a certain standard and the 
active ingredient is the same, I trust that. Individuals will sometimes come 
and tell you that some medications work better than the others, is that just 
an individual metabolic issue, or a placebo effect, you never know. In a 
case like that, I would just say no generic, only original to be given and 
they benefit.    
- No. most of us have figured out ways to wiggle off the hook if we want to 
and I’m sure most of the other physicians have told you the same thing – 
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not that I’m going to tell you any names! 
- If you really wanted a person to get a specific drug, if you dot the I’s and 
cross the T’s on the paperwork, they are going to get it. It is very seldom 
have I – but I will say this, because the suggestions have been made that 
ODB will pay for X,Y and Z, I do think about costs for particular 
individuals and I will say well we haven’t tried this yet, so let’s go with it 
first, I will do that. But many, many times, when you want a particular 
drug that you have to do a Section 8 for your patient has already tried 3 or 
4 different things because of drug samples. And we can give somebody 
who doesn’t have any money to pay for a particular prescription, you try 
them on the sample, you say give this stuff a shot and come back and let 
me know how it works in a month or so. They come back and say well it 
doesn’t work, so you try something else – well it doesn’t work. Then you 
go to ODB, and going without the common things that they will let you 
prescribe and then you have to go to the section 8 to say they actually 
need this particular drug because the others didn’t work. But sometimes, 
you can’t do all of that and you know that the drugs are particularly better. 
I think the thing is the ODB lists of medicines might not quite be as up to 
speed as what the physician in the community wants to use. There is a lag 
there, there definitely is. And you will have physicians in the community 
doing off label use of stuff that ODB won’t pay for so then you have to 
make up nonsense so they can end up getting the drug that they want. So 
most of us will do that without too much of a problem. But that’s because 
the ODB committee – I don’t know how often they meet – do they meet 
once a month or something and say should we put this on the ODB list or 
not? And that’s the one thing that we would probably find fault with – is 
the drugs that are commonly used by us, for example chronic pain 
management, around here, that is a big problem, and certain medications 
that are going to be used for chronic pain managements comes right out of 
the books and journals that we read are not covered by ODB under their 
set of guidelines so the only thing we can do is make up the person to have 
that problem so they can fit the guidelines to get the medicine that they 
need. And like I said, most of us would probably jiggle the box because 
we are more up to speed on things as frontline physicians perhaps, than 
the ODB committee who says we have to dot the I’s and cross the T’s and 
watch the bottom line. Most physicians that I would work with very 
seldom worry about bottom line costs and it is simply because we deal 
with the microcosm. We are dealing with one patient or 2, sitting in an 
office across from us, and I can’t worry about the entire cost of medical 
therapy for the province of Ontario when I have a patient sick in front of 
me. And that’s because that’s the nature of the business so the ODB 
committee really has to look at things from the entire province’s point of 
view, otherwise we go broke so we need them and I appreciate them and I 
wouldn’t want their job. But in terms of the rest of us, if I have a particular 
drug I have to give someone, I will jump through hoops to make sure that 
they get it. But I certainly will take the guidelines and pick the cheapest 
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because one of the things that I have found is that there sometimes isn’t a 
great deal of difference between any of them. 
- I have often wondered if the government should get into the business of 
making their own drugs. That is a creative solution but they don’t want to 
be in business but I can tell you right now that very few drug companies 
are going out of business and they all post a profit and if Ontario is 
picking up the tab for that then those companies are making a lot of 
money off our back. To me it is a bit Ludacris, that you are going to pay 
for doctors therapy, people in the hospital, but 60-80% of everything we 
do involves pharmaceuticals that the government doesn’t pick up the tab 
for and that’s the therapy, that’s why people get better. The drugs that you 
give schizophrenics is why they don’t end up in Emerg down on Queen St. 
in Toronto, the drugs you give those heart patients when they are 45 and 
can’t afford them, that is what keeps them out of hospital. So having the 
ODB is very very good for business. And if it is an expensive program 
then maybe the government should figure out ways of making it cheaper 
for themselves. 
- I: Actually, let’s go back to this, you mentioned earlier that you will do 
whatever you need in order to get a patient the medication that they need, 
so going back to the LU codes, you say certain LU codes will be used 
even if they don’t qualify? 
- P: in who’s strict of sense? One of the LU codes says you can use this 
drug if they have been on 2 or 3 prior drugs of similar nature that have 
failed. Well ok, sometimes it may not be three, it may be 2 so ya officially 
the criteria wouldn’t be met. And that of course is creative accounting on 
the part of the physician. But remember the physician doesn’t get anything 
out of this, why is the physician doing this? Because he’s got a patient he 
thinks he’s got a better drug for and doesn’t want to wait 6 months it’s 
going to take to try three different drugs when he has one in front of him 
that he knows will do the job today. So in terms of delaying what a patient 
gets you’re right. If I’m going to have a wait on my hands that I think is 
unreasonable, I think a lot of physicians will fudge things and you can’t 
quote me on that one! 
- I: and do you want to see changes with the LU codes? 
- P: for the time it takes for me as a physician now that I’m using a 
computer, to fire in an LU code, after they have given me the five or six 
different ones that I can choose, I don’t have a problem doing that at all. I 
mean it takes more time on my part but I don’t have a problem doing it. I 
mean some people might bark at the fact that the ODB should be every 
single drug out there, and I would disagree with that, I think the ODB has 
to be put in place because there has to be checks and balances, this is not 
an enormously expanding, never ending open ended pie that just keeps 
getting bigger. We have this much to deal with and we have to divvy it up 
appropriately so having checks and balances on the system, I’m quite 
comfortable with. And for the time it takes me to put an LU code in that I 
know is probably going to work, I fire in a couple of codes, the person 
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gets the drug they need and we are home free. So I don’t have a problem 
with it, the system works pretty well, I think so. I think the only thing 
would be is that if the current standard of practice is that a certain drug is 
used for specific type of syndromes, then it would be nice not to have to 
jump through hoops to get somebody the drug in a timely fashion. And I 
think that’s the thing, timely fashion has got to be one of those things that 
the patient and I decide, it shouldn’t be decided in a committee someplace 
else. Because there are going to be people that are going to be failing 
rather quickly and if you have to wait x amount of weeks or months to try 
alternative therapies before things start going south on you, you are going 
to feel bad that you weren’t able to help that person upfront so you want to 
be able to get stuff on board fairly rapidly but firing in an LU code it 
always comes, they say fine and pick it up. 
- To a small extent. The LU codes can be an issue at times when the code 
doesn’t automatically match my need for a pretty good medications so for 
example low molecular weight heparin in people who are anti-coagulated, 
some people who are anti-coagulated have to go for a short period of time 
back on their heparin such as pre-operatively and post operatively but the 
codes don’t allow you to do that so then you either have to, basically 
fraudulently use an incorrect code, or make the patient pay but I would say 
that is less frequent. The only thing with the LU code, is that they add an 
extra wrinkle when it comes to prescribing and I’m not really sure that the 
system benefits from that strategy. So LU codes while a bit of a nuisance 
aren’t an overwhelming obstacle. Section 8 I find a big nuisance. So you 
know, I think if ODB wants to be more straight forward then they should 
be evidence based in their approach to our use of medication, support the 
use of medication for which there is sufficient solid evidence be reluctant 
on others. So section 8 is too time consuming in a busy practitioner’s day. 
- I guess – that wasn’t already mentioned – I mean it is accessible, the fact 
that I believe patients can go to different pharmacies I mean it is available 
throughout the province, if someone is away on holidays, you know they 
can still get their drugs covered. In general I think they try to practice 
evidence based medicine so they are not putting the newest drug on the 
list just because the pharmaceutical company thinks it is a good idea, you 
know, I believe that they make an effort to put drugs that are both cost 
effective and most beneficial to the patient. I think in – I’m trying to think 
of some specific examples, for the most part, drugs that I want to prescribe 
are covered by it.   
- I think it is a good thing that when the people come to the ER department, 
that they are able to access, if the person is on ODB, the ER is able to 
access the medication records, that is a very valuable service. They can go 
into the database – registration at ER is authorized to look up a record. So 
then you have elderly people who do not have a copy of their medication 
list or didn’t bring their pills with them and they are able to access it, so 
that is a huge improvement, it has been around for 8 or 10 years. 
- my overall experience with ODB is good – it covers many drugs that 
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people need and who can’t afford or do not have any source of income to 
pay 
- my experience as a family physician is good 
- I would not say limiting, I’d rather say it takes longer to find LU code, and 
sometimes I forget to put LU code or I don’t know it is covered, patients 
comes back for the code – it happens rarely but when it does it takes up 
clinical time. 
- Sometimes I wish I could choose another medication for patient but if it is 
not covered by ODB, then patient can’t pay 0 I wish ODB would cover 
more and more medications 
- For the most part no. 
- Most drugs we use with an LU and it goes through fine – but section 8 – 
they deny everything. I don’t use expensive drugs, but when they don’t 
work, we have to go to section 8. I don’t like section 8 very much but 
ODB in general is good. It helps patients get their medications. It is not 
VERY restrictive, but the problem I have is they take meds off the list and 
then I have to turn to old medications that don’t work, or don’t work as 
well. 
- LU is ok, for most seniors. Once patient is able to get medication that they 
need, then I’m fine. The only concern I have is removing meds from the 
list sending you back to ancient meds. I do not like section 8 at all 0 most 
times they decline you. It is a waste of time, what is the point? 
- P: section 8 yes – I have had a bad experience once and I have not been 
desperate enough to use section 8. If a medication – there is a pain 
medication that at the end of the year I have to do section 8 after one year, 
what I have actually done is to switch patients to a different pain 
medication so I don’t do section 8. for the LU codes, no I have not have 
problems with that. Maybe because I just put the code. Once in a  while I 
have had to read ok this patient does not qualify for this code and I will 
tell them, most of the choose to pay for it, if I have samples, I give it to 
them, but I would say that would be like 1% of my practice so there hasn’t 
been any problems with limitations with LU codes.   
- Nobody really likes LU codes, it is something I have learned to live with 
during my career as a family physician. It sort of struck home to me 
because I teach family medicine residents and they said how do you learn 
about LU codes? And I realized like there is no real rhyme or reason – 
there is no logic to it because my residents will write prescriptions and 
there is no flag within – like there is no warning that something is LU 
until you get a call from the pharmacy back. And I mean no one is – I 
can’t tell my residents to go and read the LU website and memorize them, 
it is just something you have to learn to do by experience. So myself 
personally, I guess I have the drugs I prescribe most often, I have the LU 
codes memorized and so it is just a matter of doing the prescription and 
putting the LU code in. I see it as a bit of a game, because I am always 
trying to avoid the pharmacy calls and trying to do the best for my patients 
to try and prescribe something that is covered for them.    
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- The section 8 forms, we have fewer of those to do than we used to, it was 
always frustrating when you get a notice that your section 8 approval for 
your patient was going to run out in 4 weeks or whatever, it just seemed 
like an exercise in useless paper work because it was almost always 
approved I’d complete the form, I’d fax it off and at some point there was 
like long, long wait lists for getting these requests back so I had the sense 
that I was doing the work and then it was just sitting in a pile somewhere 
at the ministry and someone with no medical knowledge was just basically 
giving it a stamp and approving it so it was creating a barrier for me and 
also the patient If they didn’t get their approval in time.  
- I: but in general when you do submit the section 8 forms, they do come 
back approved? 
- P: yes because I believe I take care to choose the patients appropriately 
and I try to choose the patients who qualify for it. 
- I would be happy to see the LU codes and section 8 forms – just get rid of 
them. At some point in the program either just say this drug is either 
covered or it is not and if it is covered, these are the patients it is 
appropriate for. But sometimes I think it would just be easier to say just 
cover the stupid drug and pay for it! And there is less administrative work 
for the government’s end and less work for pharmacists and physicians 
and hopefully for the patients’ benefit. 
- (when asked if any rejections of section 8 requests) Oh all the time, the 
section 8 forms often come back and say we need such and such data to 
further assess the situation and oftentimes the data -  they want to see 
evidence that the medication made a difference with hemoglobin A1C for 
example, when I think certain drugs were on EAP before, but patients 
can’t try it if they don’t have coverage and we don’t have samples to give 
them so we don’t have that data to give them and then there is no point, 
the process stops, you can’t ask further for ODB to cover it! And some of 
it are flat out rejections,  - we reviewed the data about this medication, we 
found this medication is of no clinical benefit compared to the existing 
medications that are on ODB benefit sand because the cost difference is so 
dramatic, we feel that, we are listing only these drugs as opposed to the 
ones you are requesting. And that’s fine, there is some of that too but 
again, why do I need to write a letter,  three months later get a response to 
tell me no, if we do the education ahead of time, you save me all that 
energy and wait for that patient and I could  be trying something else for 
that patient. What happens is patients wait and then they get a no, and they 
put all their hopes on this medication when they could have been tried on 
something else. 
- I hardly even do it now, if the medications are not easily covered on ODB, 
or LU, I probably avoid it, you know, I do do some in extenuating 
circumstances, but I seem to tend to avoid it. And I can’t say that I’ve 
done any homework recently in how ODB and how they develop their 
criteria in what’s covered straight up, what’s covered by LU and what’s 
covered by section 8. 
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- I: and did they approve it? 
- P: no I guess that was a bad experience after all the wait, I can’t remember 
the excuse they gave, it was almost four years ago, but at the time it made 
sense, there was no reason to say no to the request so since then I have not 
done section 8 I either swap or look for samples.   
Prescribing 
habits 
- I think for GPs, depending on your practice preference, there are certain 
GPs who will prescribe newer medications once they come out on the 
market, others will take a few months once they see their colleagues are 
using them and others will wait even longer to see if there are guidelines 
that recommend certain medications. 
- If you are one of the physicians who wants to prescribe new medications 
as they become available, then it is a problem with getting it approved, 
especially if there are alternate medications - Alternative medications that 
are probably older and not as effective and possibly, usually, if I did 
choose a newer medication is because the patient tried an older one and it 
wasn’t effective 
- I think the rationale for them choosing medications that they prescribe – 
maybe that they have not found acceptance into really strict treatment 
guidelines before they are approved 
- Maybe the time for medications to enter the formulary is probably too 
long for certain medications that are shown to be effective quite quickly 
after started in use. I think probably the oncologist would feel that way for 
medications that are known to work but don’t have approval.  
- I don’t mind trying new medications for patients who have failed older 
medications, I’m just left giving them samples to see if it does work but it 
is a problem if it does work and they don’t have the finances, or they are 
not in the program, or the program doesn’t accept coverage. 
- Sometimes they cover something but only if you write it a specific way 
- It should be covered without writing the prescription in a specific way 
- Example: I ordered a steroid with lidocaine and the patient had to 
pay for it. However, if I ordered the steroid and lidocaine 
separately, and mixed it myself, it is covered. Patient had to pay 
for it because I didn’t know, but now I ask for it separately and 
mix it myself. 
- I: you mentioned when you started that there are some drugs that you are 
used to prescribing that are not covered. What did you have to do – did 
you submit a section 8 request or write a whole new prescription? 
- P: I completely changed – I have never,  I did a section 8 once when I was 
training and I didn’t like it. The fact that I had to fill out that form and 
wait for them, I have never done it since then. So what I do is change he 
prescription or I look for samples and give the patients samples. And I 
hope the pharmaceutical companies continue to bring the samples because 
if they don’t – I did the section 8 once and it was more like a teaching 
thing from my preceptor and we were waiting and waiting and oh my 
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